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INTRODUCTION 
Diabetes mellitus (DM) is a debilitating disease that over the last 
few decades has undergone a lot of research and a lot has been 
understood about the pathophysiology of the disease. Diabetic macular 
edema is the most common cause of visual loss in the diabetic population. 
It was demonstrated in 1985 by the Early Treatment Diabetic 
Retinopathy Study (ETDRS) that focal (direct/grid) laser 
photocoagulation reduces moderate vision loss from diabetic macular 
edema (DME) by 50% or more. A number of studies along with the 
ETDRS have also shown the adverse effect which the lasers can have on 
the ocular tissue thus compromising the outcome of the laser treatment. 
Thus, many newer laser machines that work through varied mechanisms 
and wavelengths have been developed over recent years to reduce the rate 
of complications.  
The variety of lasers available today has given an added dimension 
to the treatment of Diabetic Macular edema. Its imperative to strike a 
balance in a laser which will have the maximum effect and still cause 
minimal damage.  
Our aim in this study is to evaluate the efficacy of the 577 nm laser, 
which is a yellow light laser, and compare it to the conventional 532 nm 
green laser that is widely used. The 577 nm yellow wavelength laser 
when compared to the 532nm green light has a higher affinity for 
oxyhemoglobin and a slightly lower affinity for melanin and almost no 
affinity for macular xanthophylls. Yellow light is also scattered very little 
during its transit through the ocular tissue and causes minimal 
photochemical reactions in the surrounding tissues.  
Thus the major advantage in using the 577 nm yellow laser 
theoretically would be to reduce energy requirement and to obtain the 
same results as with green 532 nm. The reduced energy would lead to less 
retinal toxicity and damage due to reduced absorption by the 
xanthophylls. Our objective in this study would be to observe whether the 
theoretical advantage translates to a more effective treatment in reality. 
 
  
HISTORICAL PERSPECTIVE 
1946 – Meyer Schwickerath first started to investigate the creation of 
retinal burns using sunlight. 3 
1958 – Xenon arc lamp was introduced which emitted spectrum similar to 
sunlight and offered a longer life lamp with relatively high uniform 
output. 4 
1960 - Maiman introduced the first ophthalmic laser which used a ruby 
crystal. The ruby output had a wavelength of 694nm. Was highly 
coherent, allowing for better transmission through the ocular media with 
more precise retinal burns. 5 
Late 1960s – Argon blue laser revolutionised the field of ocular laser 
photocoagulation. The argon wavelength was relatively well absorbed by 
haemoglobin permitting direct closure of retinal vasculature. 6 
Early 1980s – Krypton red laser was introduced which penetrated through 
cataracts and haemorrhage extremely well and had negligible absorption 
by macular xanthophylls.7  
Mid 1980s – Dye laser was developed & offered a continuous spectrum 
of wavelength from 560 – 640nm. The yellow (577nm) and red (640nm) 
wavelengths became the most clinically useful. Dye yellow emerged as 
an ideal wavelength for closing vascular lesions, since it is near the peaks 
of the haemoglobin absorption curves. The benefits of dye red were 
virtually identical to those of Krypton red.8 
Late 1980s - The development of the diode laser in the late 80s produced 
a compact, portable air cooled instrument with an output of 805-810nm. 9 
Early 1990s – Solid state, frequency doubled ND:YAG laser was first 
described in 1971, but did not become commercially available until early 
1990s. The absorption characteristics of its wavelength, 532nm, most 
closely resemble those of dye yellow. 10 
Mid 2000s – The development and launch of the solid state yellow laser 
(577nm) which has recently become commercially available. It has 
similar advantages to that of the dye yellow laser and is a more stable 
substance making it a more viable product.  
 
 
 
 
 
DIABETES MELLITUS 
Diabetes mellitus is a major of metabolic disorder characterised by 
high blood sugar, due to insufficient production of insulin or due to poor 
responsiveness of the peripheral tissue to insulin. 12 The increased 
osmolarity of the blood due to the increased level of blood sugar causing 
the classical triad of symptoms of diabetes namely, polyuria (frequent 
urination), polydipsia (increased thirst) and polyphagia (increased 
hunger). 
Diabetes Mellitus can be broadly divided into three major types: 
a) Diabetes Mellitus Type 1: This results from the inability of the 
pancreatic tissue to produce insulin and therefore the patient 
requires exogenous insulin. Hence this condition is referred to as 
Insulin Dependent Diabetes Mellitus (IDDM).  
b) Diabetes Mellitus Type 2: This condition is characterised by an 
increased peripheral resistance to the insulin produced. This 
increased resistance is maximal in the peripheral adipose tissue. As 
this disease can result even in the presence of normal levels of 
circulating insulin, it has been referred to as Non-Insulin 
Dependent Diabetes Mellitus (NIDDM) 
c) Gestational Diabetes: It is characterized by the development of a 
high blood glucose level during pregnancy in a previously normal 
patient. It may however precede development of type 2 DM. 
Insulin Dependent Diabetes Mellitus:  
Type 1 diabetes mellitus by an immune mediated pathology is 
characterized by loss of beta cells in the pancreas which produce insulin. 
An autoimmune T cell mediated attack causes destruction of the Beta 
cells in the islets of the pancreas16. Unlike in type 2 diabetes, the 
sensitivity and responsiveness to insulin in the peripheral tissues is 
essentially normal. Type 1 diabetes usually affects the younger age group 
and onset occurs in childhood or early adulthood.  
Non Insulin Dependent Diabetes Mellitus:  
In Type 2 diabetes mellitus there is an increased peripheral insulin 
resistance, which may or may not be combined with relatively reduced 
insulin secretion 12.  The increased peripheral resistance of body tissues to 
insulin is believed to be due to defects or decrease in the amount of 
the insulin receptor. Type 2 diabetes usually presents only in adults and it 
is the most common type. 
Signs and symptoms 
The classical triad of symptoms of uncontrolled diabetes mellitus are 
weight loss, polyuria (frequent urination), polydipsia (increased thirst) 
and polyphagia(increased hunger). 22.  The origin and progression of 
signs and symptoms is rapid (weeks or months) in type 1 diabetes, where 
as they usually develop much more slowly and may be subtle or absent in 
type 2 diabetes. 
Emergencies in Diabetes Mellitus: 
A) Diabetic Ketoacidosis: It is most common in Type I Diabetics. 
There is a state of metabolic dysregulation which is characterized 
by the smell of acetone and a rapid, deep breathing known 
as Kussmaul breathing.  This is accompanied by nausea, vomiting 
and abdominal pain, and altered states of consciousness. 
B) Hyperosmolar Nonketotic Coma:  
It is more common in type 2 diabetics though its incidence is rare. 
It is characterized by a very high blood sugar with a very high 
blood osmolarity resulting from the raised sugar levels. It is mainly 
caused due to the dehydration. 
 
 
Long term Complications: 
The risk of long term complications increases with the duration of the 
disease in all forms of diabetics and typically takes about 10-20 years for 
them to develop. Diabetic complications can be broadly divided in to: 
a) Macrovascular complications: It is caused by the accelerated 
atherosclerotic changes in the large vessels that occurs in diabetes 
and can lead onto ischemic heart disease, stroke and peripheral 
vascular disease. There is a two fold increase in the risk 
of cardiovascular disease 23.  
b) Microvascular complications: It results due to the damage that 
occurs in small blood vessels 24 and can lead onto diabetic 
retinopathy, diabetic nephropathy and diabetic neuropathy.  
Pathogenesis: 
The regulation and uptake of glucose from the blood stream into the 
tissues is mainly governed by Insulin. Hence either a lack of insulin or an 
increased insensitivity to it plays a central role in all forms of diabetes 
mellitus. 
The carbohydrate content in the food is digested in the gut and is broken 
down into its most simple form the monosaccharide glucose which is the 
principal carbohydrate energy source used by the body. From the islets of 
Langerhans in the pancreas the beta cells secrete Insulin which is released 
into the blood stream in response to rising levels of blood glucose usually 
after a meal. About two-
glucose from the blood for use as fuel, for conversion to other needed 
molecules, or for storage.
Insulin also plays a central role in the storage of glucose in the form of 
glycogen in liver and muscle cells. The release of insulin 
falls when there is a lowered blood glucose levels. The hormone glucagon 
acts in the reverse manner as insulin and is released from the alpha cells 
of pancreas. It cause breakdown of glycogen to glucose and enables 
thirds of the body's cells require insulin to absorb 
 
from Beta cells 
 
raising blood glucose levels. This usually occurs in the liver cells when 
the level of glucose is low in the blood stream.  
Insulin plays a central role in other anabolic processes, such as cell 
growth and duplication, protein synthesis, and fat storage. The insulin 
levels either being high or low acts as an important trigger in controlling 
bidirectional processes of metabolism from a catabolic to an anabolic 
direction, and vice versa. In particular, a low insulin level is the trigger 
for entering or leaving ketosis (the fat-burning metabolic phase). 
When insulin levels are insufficient or if there is insulin insensitivity or 
resistance then glucose will not be absorbed properly by those body cells 
that require it, nor will it be stored appropriately in the liver and muscles. 
The resultant effect is a persistently elevated levels of blood glucose and 
subsequently there is poor protein synthesis, and in increased fat 
breakdown resulting in ketosis and acidosis. 
With the gradual increase of the glucose concentration in the blood is 
beyond the renal threshold that is above 10mmol/L, there is 
incomplete reabsorption of glucose in the proximal renal tubuli. This 
results in release of glucose in urine i.e. glycosuria. This causes increased 
osmotic pressure of the urine and decreased reabsorption of water by the 
kidney, resulting in increased urine production (polyuria) and increased 
fluid loss. This increased fluid loss results in a dehydrated state that 
triggers the central thirst mechanisms resulting in increased fluid intake 
(polydipsia).   
Thus diabetes with its myriad presentation is a systemic disease which 
with its microvascular and macrovascular complications can cause 
increased morbidity and mortality if not effectively controlled.  
 
 
 
 
 
 
 
 
 
 
 
 
DIAGNOSIS AND INVESTIGATIONS OF DIABETES MELLITUS 
Diagnosis 
Diagnosis of Diabetes 28, 29 
 Fasting 
(mg/dl) 
Post Prandial 
(mg/dl) 
HbA1c 
Normal <110 <140 <6.0 
Impaired glucose tolerance >110 but 
<126 
>140 but <200 6.0–
6.4 
Diabetes mellitus >126 >200 ≥6.5 
The criteria for diagnosing diabetes mellitus include the following:  
1) Fasting blood sugar above 126mg%.  
2) Post prandial blood sugar, that is the level of measured plasma 
glucose after 2 hours of consumption of 75g of glucose, which is 
greater than 200mg%. 
3) The signs and symptoms of hyperglycemia accompanied by a 
raised blood glucose levels.  
4) Glycated hemoglobin (Hb A1C) ≥ 6.5%(30)  
It is preferable to measure a fasting glucose level because of the ease of 
measurement rather than the considerable time taken up by conducting 
the glucose tolerance testing as it takes two hours to complete and offers 
no significant prognostic advantage over the fasting test. 31  According to 
the current criteria two fasting glucose measurements above 126 mg/dl is 
considered diagnostic for diabetes mellitus. 
Those with fasting glucose levels in the intermediate range from 110 to 
125 mg/dl are grouped as impaired fasting glucose. 32 
Candidates with plasma glucose above 140 mg/dl but less than 200 mg/dl, 
which is measured two hours after a 75 g oral glucose are grouped as 
impaired glucose tolerance.  33. 
Glycated hemoglobin is more sensitive predictor of risk of cardiovascular 
disease and death than fasting glucose.  34 
Glycated hemoglobin (HbA1c) 
The content of average plasma glucose concentration over a period of 
time can be measured indirectly by the glycated haemoglobin. The 
glucose in the blood stream through a non-enyzmatic glyaction pathway 
gets incorporated into the haemoglobin chain. As the amount of blood 
glucose increases the glycated haemoglobin also increases. The level of 
glyacted haemoglobin lasts as long as the life span of the RBC containing 
the haemoglobin. Therefore the glycated hemoglobin serves as a marker 
of the level of blood glucose over the last 3-4 months.  
In 2010, American Diabetes Association Standards of Medical Care in 
Diabetes devised the additional criteria for diagnosis of diabetes being 
HbA1C of >6.5%. 25 
A high level of HBA1C also serves as a marker for cardiovascular 
disease, nephropathy, and retinopathy. Monitoring HbA1c in diabetic 
patients may help avoid long term complications. 26 
 
 
 
 
 
 
 
 
 
 
DIABETIC MACULOPATHY 
Among patients with diabetes the most common cause of visual 
impairment is Diabetic macular edema. The pathogenesis of DME is 
complex and multifactorial. It occurs mainly as a result of disruption of 
the blood--retinal barrier, which leads to increased accumulation of fluid 
within the intraretinal layers of the macula. 38,43,87 
 
A. CLINICAL DESCRIPTION AND CLASSIFICATION 
Diabetic macular edema is diagnosed as retinal thickening in the macula 
using Fundus slit lamp biomicroscopy. The Early Treatment Diabetic 
Retinopathy Study (ETDRS) defined DME as retinal thickening or 
presence of hard exudates within 1 disk diameter of the centre of the 
macula. This definition has been used consistently in most of the diabetes 
related research studies. 51,71,72 To characterize the severity of macular 
edema and for treatment guidelines, the term clinically significant 
macular edema (CSME) is used.  
Macular edema is clinically significant if one of the following conditions 
is present:  
retinal thickening within 500 microns  of the centre of the macula; 
(or) 
hard exudates within 500 microns of the centre of the macula if 
associated with thickening of the adjacent retina;  
(or) 
 a zone of retinal thickening  of atleast one disk area in size, at least part 
of which is within 1 disk diameter of the centre of the macula.  51,71 
B. FOCAL VERSUS DIFFUSE DIABETIC MACULAR EDEMA 
Clinically significant macular edema is further classified into focal or 
diffuse, depending on the leakage pattern seen on the fluorescein 
angiogram (FA). Leakage noted on FA is not synonymous with edema or 
thickening. The FA is used to identify areas of increased 
vasopermeability, for example, leaking microaneurysms or capillary beds, 
and to evaluate retinal ischemia. Leakage on the angiogram does not 
necessarily indicate retinal edema since extracellular edema requires that 
the rate of fluid ingress into the retina (i.e., as indicated by leakage on the 
FA) exceed the rate of fluid clearance from the retina (e.g., via the RPE 
pump). 
In focal CSME, 42 multiple microaneurysms produce focal points of 
retinal hyperfluorescence on FFA.39,238. The discrete leaking 
microaneurysms are thought to cause retinal thickening. Commonly, 
these leaking microaneurysms are surrounded by circinate rings of hard 
exudates. The exudates are lipoprotein deposits in the outer retinal layers. 
40 In diffuse DME, there is a diffuse hyperpermeability response of the 
retinal capillaries or intraretinal microvascular abnormalities within the 
macula that produce areas of diffuse leakage are noted on the FA.  39,52 
There may be a generalised breakdown of the inner blood retinal barrier 
which can be associated with cystoids edema with fluid accumulation in 
the outer plexiform layer. 41,68  
Focal DME is characterized by well-defined, discrete areas of leakage 
from the microaneurysms on the FA, in comparison to diffuse DME, 
which is characterized by generalized areas of leakage in the area 
centralis. Furthermore, focal DME is responsive to focal laser 
photocoagulation, whereas diffuse DME represents a more challenging 
clinical situation and is refractory to laser photocoagulation in many 
cases.54,58,74.  Grid pattern of laser treatment may be helpful in certain 
cases. Compared to those with less severe non-proliferative diabetic 
retinopathy, the relative risk for diffuse macular edema is 6.2 times 
greater in patients with very severe nonproliferative diabetic retinopathy 
and 7.7 times greater in patients with proliferative diabetic retinopathy. 53  
 
 
C. EPIDEMIOLOGY 
In one study, the incidence of DME over a 10-year period was 20.1% 
among patients diagnosed before age 30 years (younger onset) and 39.3% 
among patients diagnosed after age 30 (older onset). 191 Diabetic macular 
edema, in this study, was defined as thickening of retina within 1 disk 
diameter of centre of the macula. The Diabetes Control and 
Complications Trial (DCCT) reported that 27% of patients develop 
macular edema within 9 years of diabetes onset. 37,61,71,72,100  . The 
frequency of DME increases with the duration and the severity of 
diabetes. 70,80 .  Older onset diabetic patients have a tendency to develop 
macular edema earlier in the course of their disease (prevalence: 3-8% 
with up to 3 years of disease duration) compared to younger onset 
diabetic patients (prevalence: 0.5% with up to 10 years of disease 
duration) 
PATHOGENESIS 
A. BLOOD--RETINAL BARRIER 
The common pathway that results in DME is disruption of the BRB 49.  
The BRB compartmentalizes the neurosensory retina from the vascular 
component of the eye. Maintenance and proper functioning of the BRB is 
a complex process and involves the interaction of several factors.  
The BRB consists of two major components: the outer barrier and the 
inner barrier. The inner BRB is a biological unit formed primarily by 
tight junctional complexes between retinal vascular endothelial (RVE) 
cells and a well-differentiated network of glial cells (astrocytes and 
Muller cells) that operates to maintain a low permeability environment; 86  
the outer BRB is formed by tight junctions between retinal pigment 
epithelium (RPE) cells and includes zonula occludens with prominent 
desmosomes. 45,48 
 
1. Inner Blood--Retinal Barrier  
The inner BRB comprises capillary endothelial cells with intercellular 
tight junctions within a closely differentiated network of neurons and 
glial cells. 59,86,96. The tight junctions include zona occludens, which serve 
as one of the most important elements in regulating BRB. Several cells 
assist in maintaining the inner RB as mentioned subsequently. 
 
a. Glial Cells 
Astrocytes guide the migration of retinal vessels during fetal life and, in 
combination with Mueller cells, induce the formation of barrier properties 
and tight junction proteins. 60,96,98 . The astrocyte foot processes very 
tightly surround the retinal vascular endothelial cells creating a 
microenvironment of BRB. Structural and functional changes are noted in 
neurons and glial tissue of the retina in early diabetes, much before 
changes in the retinal vasculature are noted. 40,76,78,84 
 
b. Pericytes 
Pericytes are microvascular mural cells that provide vascular stability 62 . 
Pericytes play an important role in controlling the inner BRB. 
Morphological changes of pericytes are seen in early diabetes; the cells 
become rounder, with reduction in the number of processes, and develop 
impaired cell adhesion to the underlying matrix 50.  Apotosis of retinal 
capillary pericytes occurs during early diabetic retinopathy. 77.  Loss of 
pericytes ensues and leads to the weakening of the pericyte sheath, 
outpouching of capillaries, microaneurysms, and breakdown of the inner 
BRB. 47,50,73,93,99. Loss of pericytes in early diabetic retinopathy may be 
related to the retinal capillary endothelial death that leads to capillary 
dilation, microaneurysms, retinal ischemia, production of VEGF, 
increased vascular permeability, and angiogensis. 
 
C. Vascular Endothelium 
Endothelial cell death is a hallmark of diabetic retinopathy. It has been 
shown that endothelial cell death precedes the formation of acellular 
capillaries, which progresses over time. The resultant acellular capillaries 
lead to irreversible retinal ischemia. The exact mechanism that initiates 
this cascade of events in diabetic eyes is still largely unknown. Abnormal 
adhesion of leukocytes to the diabetic vascular endothelium is present 
early in the disease and is considered an important inciting factor in 
animal models of diabetic retinopathy, which is significantly associated 
with retinal capillary occlusion and breakdown in BRB. 64,65 
 
D. Retinal Vascular Leukostasis 
Although diabetes is not traditionally considered an inflammatory 
disease, increased numbers of leukocytes are noted in the retinal 
vasculature. 67 Leukocyte adhesion to the capillary endothelium is one of 
the first histological changes seen in diabetes. 64,82,91.  Leukostasis within 
the retinal vasculature may play a crucial role in the endothelial cells 
death. Leukocyte adhesion to the diabetic retinal vessel wall causes 
apoptosis of pericytes and endothelial cells, vascular obstruction, 
subsequent non-perfusion, and release of cytokines that increase vascular 
permeability. 67,82 
 
 
 
e. Advanced Glycation End-Products (AGEs) 
Chronic hyperglycemia leads to the formation and accumulation of AGEs 
that may be a primary contributor to diabetic microvasculopathy. AGEs 
form on the amino groups of proteins, lipids, and DNA with complex 
cross-links and lead to modification in the structure and function of 
proteins. 64 
Advanced glycation end-products activate ICAM-1 in the endothelial 
cells, possibly by increasing the levels of transcription factors such as 
NF-kappa B. 65 There is indirect evidence to show a strong correlation of 
AGE products with leukostasis. Retinal leukostasis and disruption of the 
BRB has been shown to occur after the infusion of AGE in normal mice 
82
. Increased expression of ICAM-1 and CD-18 parallels leukocyte 
adhesion. Specific inhibition of ICAM-1 or CD18 prevents leukocyte 
adhesion and breakdown of the BRB. 64.  Advanced glycation end-
products are found in vitreous, especially at the vitreoretinal interface on 
the posterior vitreous cortex and the internal limiting membrane (ILM). 
Their receptors, RAGEs, are attached to the footplates of the Muller cells 
spanning ILM and the external limiting membrane. 
 
 
 
F. ROLE OF VASOACTIVE FACTORS 
Several vasoactive factors (e.g., VEGF, protein kinase C [PKC], heparin, 
angiotensin II, PEDF, metalloproteases) and biochemical pathways may 
be affected by sustained hyperglycemia in diabetes, which may influence 
the development of structural and functional changes in diabetic 
retinopathy 44,56,90,100. Increased levels of histamine seen in diabetic 
patients increases vasopermeability directly and also indirectly by 
upregulating PKC. 
 
VEGF is increased in the retina of diabetic rats as well as in diabetic 
humans. VEGF is produced by RPE cells, ganglion cells, Muller cells, 
pericytes, endothelial cells, glial cells, neurons, 55,95 and smooth muscle 
cells of the diabetic retina. Upregulation of VEGF by hypoxia occurs in 
all of these cell types 94,95. Muller cells are the most important source of 
VEGF in the retina due to their high rate of glycolysis. VEGF produces 
conformational changes in the tight junctions of retinal vascular 
endothelial cells 38. VEGF induces phosphorylation of the tight junction 
proteins, occludin and ZO-1, which leads to increased vascular 
permeability by phosphorylation of adherent junction and cytoskeletal 
proteins of vascular endothelial cells and induction of fenestrations in 
endothelial cell membranes. 90 Other cytokines, such as insulin-like 
growth factor-1 (IGF-1), interleukin-6 (IL-6), and PKC-beta, also 
promote the expression of VEGF and BRB disruption. Hyperglycemia 
itself can enhance the response of retinal endothelial cells to IGF-1.81 
IGF-1 can regulate the expression of VEGF in RPE cells. A positive 
correlation is observed between the serum or vitreous concentration of 
IGF-1 and extent of neovascularization in diabetic retinopathy. Insulin-
like growth factors (IGF-1 and IGF-2) are upregulated in vitreous of 
patients with ischemic retina. 88 
 
VEGF also may be associated with the early inflammatory changes seen 
with diabetic retinopathy and DME. In early diabetes, vitreous levels of 
VEGF are elevated. In rodents, increased levels of VEGF are associated 
with upregulation of ICAM-1 leading to retinal leukostasis and 
endothelial cell damage. 64,66,89  
 
C. VITREORETINAL INTERFACE 
Clinical and anatomical evidence indicates that abnormalities in the 
structure of the vitreoretinal interface may play an important role in the 
pathogenesis of DME. 63,75,97  DME may be exacerbated due to persistent 
vitreomacular traction by the residual cortical vitreous on the macula after 
PVD, thickened and taut posterior hyaloid that may or may not be 
adherent to ILM, macular traction due to tractional proliferative 
membranes, or loculation of cytokines in the pre-macular vitreous pocket. 
A diabetic retina compromised due to microvascular abnormalities may 
be vulnerable to increased exudation in the presence of any macular 
traction. 
  
OPTICAL COHERENCE TOMOGRAPHY 
OCT can be used to generate cross-sectional or three-dimensional images 
by measuring the echo time delay and magnitude of back-reflected light. 
Quantitative measurements of retinal thickness and volume can be done 
by easy non invasive modality. The quality of the scans and images 
obtained by OCT can only compared with histology specimens and is far 
superior to any other non invasive diagnostic technique. 103,104,105,106  
Since it was first described by Huang et al in 1991107 OCT has grown 
leaps and bounds. The retina was first demonstrated in vivo via imaging 
in 1993 108, the first commercially available OCT device, ‘Zeiss OCT,’ 
was developed in 1996. The axial resolution was 10mm and it had a 
speed of 100 A-scans per second. It was only in 2002 when the Zeiss 
Stratus OCT became available when OCT found a more widely accepted 
place in clinical ophthalmology. The increased speed of image acquisition 
by the Stratus OCT0, 400 A-scans per second, resulted in improved 
image quality. The improved quality of images along with widespread 
availability of clinical data showed the utility of OCT in daily ophthalmic 
practice. Though not yet available on a large scale Ultra high resolution 
OCT is capable of an axial resolution of 2– 3mm and can provide 
subcellular detail. 103. 
Time domain detection is used in Stratus OCT in which the reference 
mirror position and delay require mechanical scanning to produce A-
scans .A high speed spectrometer that measures light echoes from all time 
delays simultaneously in the spectral or Fourier-domain OCT, has 
significant advantages over time-domain detection. The reference mirror 
need not be mechanically scanned in Spectral-domain OCT and it also 
has improved sensitivity and allows for faster sampling speed and 
improved signal-to-noise ratio. Spectral domain OCT available today 
have achieved image acquisition speeds greater than 20 000 A-scans per 
second and axial resolutions of 4–7mm. 109,110 
The second inner hyper reflective band is used as the outer border of the 
retina in the SOCT Copernics and RTVue-100. The Cirrus HD-OCT & 
Spectralis OCT identify the most outer hyperreflective band as the outer 
border of the retina. These differences were detected by comparing the 
measurement of retinal thickness on the same retinas and by this Stratus 
OCT measured the lowest central retinal thickness whereas Spectralis 
OCT and Cirrus HD-OCT measured the highest.  
The best intersession repeatability was found in the Spectralis OCT 110. 
These differences are of clinical importance if the same patient undergoes 
sequential scans on tomograms from different platforms.  
 
OCT enables us to detect and rapidly quantify macular edema 112. In SD-
OCT the pictures are depicted in gray scale and not in colour scale but it 
helps accurate detection of more subtle differences in tissue reflectivity. 
114
.  
Terms used in OCT: 
(1) Retinal thickness: distance between the RPE and the ILM in microns 
excluding the subretinal fluid.  
(2) Retinal thickening: calculated value equal to the retinal thickness 
minus the population mean for the variable under consideration. 
(3) Central subfield: circular area 1mm in diameter centered on the centre 
point. 
(4) Centre point: calculated by point of intersection of the radial scans.  
(5) Centre point thickness: average of the thickness values of the radial 
scans. 
 (6) Central subfield mean thickness: mean value of the thickness values 
obtained within the central subfield. 
 
Assessment of Visual acuity by OCT:  
A good correlation has been found between the central retinal thickness 
measured by OCT and visual acuity in many studies. 102,115,120 . As 
deduced from these studies Central retinal thickness measurement by 
OCT has a more significant effect on visual acuity than does age or other 
parameters affected visual acuity like fluorescein leakage, perifoveal 
capillary blood flow velocity or perifoveal capillary occlusion  102,118  The 
DRCR.net displayed a lot of variability in results in a large study as they 
found a paradoxical improvement in vision occurred with increased 
thickening in 1–17%, and a paradoxical worsening of vision occurred 
with decreased thickening in 18–26%. These variations were probably 
due to the fact that The DRCR.net study 102 did not analyze the duration 
of existing edema at baseline nor did it have complete data regarding the 
degree of macular ischemia which could cause an alteration in the 
macular edema and its correlation with central visual acuity. 
 
Optical coherence tomography patterns in diabetic macular edema: 
OCT has provided us an excellent qualitative and quantitative method to 
classify diabetic macular edema. 120,121,126 
The types are: 
a) Diffuse spongiform macular edema 
b) Cystoid macular edema 
c) Serous retinal detachment 
d) Taut posterior hyaloids 
 
Diffuse retinal thickening is described as a sponge like swelling or 
edema of the retina with a generalized & heterogeneous image with mild 
hyporeflectivity. Some authors suggest that there must be a quantitative 
increase in the central subfield mean thickness with a value like 200 
microns on Stratus OCT. The threshold may vary according to the 
platform being used. Diffuse retinal thickening is the commonest reported 
finding via OCT in eyes with DME and are present in 88-100% of eyes 
with DME. Diffuse retinal thickening alone without any other 
characteristics patterns described by OCT is present in 36–42% 120,122,127.  
 
Cystoid macular edema is described by the presence of intraretinal, 
round or oval cystoid areas of low reflectivity that were separated by 
septae which are highly reflective. This reflectivity with the cystoids 
spaces in DME is has greater reflectivity than the ones found in cystoids 
spaces associated with Type 2 IJT according to Barthelmes et al. Due to 
the exudative nature of DME with breakdown of the inner bloodretinal 
barrier and therefore a higher concentration of protein may be the reason 
behind the increased intrinsic reflectivity in diabetic cystoid edema.. 
Cystoid macular edema is found through OCT in 44–47% of eyes with 
DME 120,122,127. 
 
Sub retinal detachments have been described on OCT as a focal, arch-
like elevation of neurosensory retina overlying an accumulation of 
subretinal fluid which is hyporeflective and the resultant space is dome 
shaped. The overlying posterior border of the retina is typically 
hyperreflective and thick due to an accumulation of unphagocytosed 
photoreceptor outer segments. SRDs under the fovea have been reported 
in 3–31% of patients with DME. 102.126.127.128.129.  
 
Vitreo Macular Interface Abnormalities (VMIAs) include the presence 
of epiretinal membranes, vitreomacular traction or both. An epiretinal 
membrane is visible in OCT as a thickened hyperreflective band along 
the inner aspect and may have the pseudohole which will appear as an 
incomplete or partial defect in the membrance. Vitreomacular traction on 
the other hand was identified by a hyperreflective band that is in 
apposition with the inner surface of the retina at a particular site(s) but is 
elevated above the surface of the retina elsewhere unlike a epiretinal 
membrane which is seen apposed right through 127,130. VMIAs appear to 
occur in 14–16% of eyes with DME 122,127. The role of VMIAs in 
recurrent or persistent macular edema has been better understood only 
after the advent of OCT.  
 
OCT has now become invaluable in the qualitative and quantitative 
assessment of DME. It helps to diagnose, prognosticate and also aids in 
delivering a targeted therapeutic approach to the various patterns of 
Diabetic Macular Edema.  
 
FLUORESCEIN ANGIOGRAPHY 
Fluorescein angiography is a gold standard method for identifying site or 
sites of leakage in Diabetic Macular edmea. 130,131 The leaking areas not 
only help us to identify the microaneurysms but targeted laser therapy can 
be given to them in the presence of an FA. Areas of non perfusion helps 
us to identify ischemic maculopathy and prognosticate and avoids 
unnecessary laser therapy.  
Kang and coworkers categorized fluorescein angiographic leakage in 
DME into three different types:  
1) focal leakage: well-defined focal area of leakage from microaneurysms 
or dilated Capillaries 
 2) diffuse leakage: It is believed to be a diffuse hyperpermeabilty 
response of the macular capillary bed 
3) diffuse cystoid leakage: diffuse leakage and pooling of dye in the 
cystoid spaces that occur in DME in the late phase of the angiogram and 
can be correlated with OCT.132 
The various patterns described above which can be elicited by FFA are 
very essential as they guide the mode of laser therapy that is to be 
administered. Focal leaks are treated with focal laser where as diffuse 
leaks are treated with grid lasers leaving a distance of 500 microns from 
the centre of the macula. 133. 
 
OCT and FFA have therefore become essential prerequisites in the 
armamentarium of investigation of the retina for diagnosing and treating 
diabetic macular edema.   
 
 
 
 
 
 
 
 
 
 
 
 
LASER PHYSICS 
Laser is an acronym for “Light Amplification by Stimulated 
Emission of Radiation”. Substances have the property to lase i.e. to 
absorb energy in uniform (either thermal, mechanical, electrical or light – 
all ophthalmic lasers presently use light as the stimulating source) and to 
emit a new form of light energy which is more useful. A substance which 
has the ability to lase possesses the unique property of transferring the 
electrons from the orbital to a second meta stable, spaced by a definite 
energy interval. Most electrons have been energised sufficiently by the 
stimulation source, so that they are in a meta stable orbit of higher 
energy. This sudden jump to a lower energy level causes the emission of 
a new form of light energy.  
BASIC REQUIREMENTS FOR A LASER 
A lasing medium is placed in a optical cavity that acts as resonator. 
The resonator cavity consists of two mirrors carefully aligned to each 
other; the laser material is in between them. One of the mirrors is partially 
transmitting so that some of the radiation will be coupled out of the 
cavity. Once the population inversion has been achieved, the laser 
radiation build up begins with some of the excited atoms in the medium 
emitting spontaneous radiation in various random directions. Some of the 
radiation however, will hit one of the mirrors and return passing through 
the medium. The radiation is re enacting in exactly the correct 
wavelength (since the material itself radiated it) and will therefore 
stimulate some of the atoms into emitting radiation, thus amplifying the 
beam. After the wave bounces back from the other mirror, it will be 
amplified as it passes through the medium again. Consequently the device 
emits a highly coherent beam because of the geometry of the cavity.  
PROPERTIES OF LASER ENERGY: 
Light emitted by a laser differs from normal ‘white’ light in the 
following ways. 
COHERENCE: 
Like the photons in a light bulb which are emitted randomly, the 
resonator effect of the laser cavity causes the photons to be synchronised 
(i.e. in phase with each other in time and space.) 
COLLIMATION: 
Since light amplification occurs only for photons that are aligned with the 
mirrors, a nearly parallel beam is produced as opposed to the diverging 
beam of an incandescent lamp. Although limited divergence occurs with 
all laser beams, it is minimal enough to provide a small focal spot when 
the light is delivered through an optical system.  
MONOCHROMACY: 
Since the photons are emitted as a result of the release of energy between 
two defined levels of the atom, the resulting light has a narrow range of 
wavelengths.  
HIGH INTENSITY: 
The light amplification of a laser can produce a beam with significantly 
more intensity than the sun.  
LASER INDUCED TISSUE EFFECTS: 
Laser can have various target tissue depending on the wavelength and 
power used. 
1. PHOTOCHEMICAL EFFECTS: 
Ultraviolet and visible light absorption induces the formation or 
destruction of chemical bonds. 134 
2. THERMAL EFFECTS: 
Most commonly encountered with retinal photocoagulation. Occurs when 
the visible or infrared light is absorbed by tissue pigments.135.  Absorption 
of laser energy results in a 10 to 20 degree temperature rise which 
photocoagulates, or denatures, the absorbing tissue. The temperature rise 
in the fundus is highly localised, limited to within 1mm of the burns 
centre. 136. Photocoagulation intensity is directly proportional to the 
magnitude and duration of the temperature rise. Protein denaturation is 
seen clinically as tissue whitening.  
Absorption Characteristics of lasers of different wavelengths:  
MAJOR 
FUNDUS 
PIGMENTS 
XANTHOPHYLLS  HEMOGLOBIN MELANIN 
ARGON BLUE 
GREEN 
(488nm) 
++++ +++ +++ 
ARGON 
GREEN 
(514NM) 
--------- +++ ++++ 
Nd:YAG 
(532nm) 
------ ++++ ++++ 
DYE YELLOW 
(577nm) 
 
------ ++++ ++++ 
DYE RED 
(630nm) 
------ + +++ 
KRYPTON 
RED (647nm) 
------- + +++ 
DIODE 
(810nm) 
-------- ----- ++ 
Most of the thermal damage created during posterior segment 
photocoagulation is achieved by the absorption of laser energy by 
melanin in the retinal pigment epithelium and choroid.  
3. VAPOURISATION: 
Possible with visible or infrared laser energy. There is micro explosion, 
when the temperature of water rises above the boiling point, as with 
carbon dioxide laser or following an overlay intense argon burn.  
4. OPTICAL BREAK DOWN: 
Occurs with infrared light of the Nd:YAG laser. An extremely high 
power results in plasma formation where electrons are stripped away 
from atoms and molecules. This leads to a shock wave that physically 
disrupts tissue. The desired disruption is independent of tissue 
pigmentation  
 
 
 
 
 
LASER PHOTOCOAGULATION FOR DIABETIC 
MACULOPATHY 
The value of laser photocoagulation for the treatment of diabetic macular 
edema has been demonstrated in a multitude of studies. 
351,52,74,137,138,141,142,149,150,151,152,153,154,155,157,158,160,168.
  
1. The Early Treatment Diabetic Retinopathy Study (ETDRS) 
Results 
The ETDRS study was a prospective, randomized, multicenter clinical 
trial. It was designed to evaluate the effects of argon laser 
photocoagulation for macular edema.  An improvement in the visual 
acuity of 16% was noted among the eyes with mild to moderate non-
proliferative diabetic retinopathy with macular edema. The visual acuity 
remained unchanged in 77%, and worsened in 7% of treated eyes. After 2 
years of follow up, there was a decline in the visual acuity with 
improvement being in only 11%, and it remained unchanged in 73% with 
worsening in 16% of untreated eyes after 2 years of follow-up. At 3 years 
of follow-up, the worsening of vision was only 12% in the treated group 
compared to 24% in the untreated eyes. If macular edema involved the 
center of the macula (vs macula-threatening edema), then the visual 
prognosis was worse, and the magnitude of the treatment benefit was 
greater. Specifically, the risk of moderate visual loss among patients with 
center involving macular edema assigned to deferral was 32% at 3 years 
vs 15% in the treatment group. Of the 350 eyes with CSME, which had 
retinal thickening involving the center of the macula, at 1 year of follow-
up, only 35% of eyes assigned to immediate photocoagulation had retinal 
thickening in the center of the macula compared to 63% of eyes assigned 
to deferred photocoagulation. The benefit of laser photocoagulation was 
statistically significant in these eyes. 51 
The risk of severe visual loss was not significantly different between the 
treatment and control groups in each category of retinopathy (i.e., those 
with less severe vs more severe retinopathy) using the previously 
described treatment criteria. At one year follow up, the risk of moderate 
visual loss was significantly lower in the treatment group compared to the 
control group. 145 Though risk of severe visual loss at 5 years follow up 
was lower in the treated group as compared to the control group, it was 
not evident whether the visual loss would be influenced by the timing of 
focal photocoagulation. 145 
It was concluded by the ETDRS investigators that early focal 
photocoagulation should be considered in all eyes with CSME. The 
treatment was associated with a lower risk of moderate visual loss, an 
increased chance of visual improvement, less loss of colour vision, and 
only minor visual field changes. 42,51,52,145 
The anatomical and functional success of eyes with diffuse DME treated 
with grid laser photocoagulation is not good. Even with multiple 
treatments, diffuse DME can be refractory to macular 
photocoagulation.140,154 .  Lee and Olk154 reported limited visual 
improvement after grid laser in their large study of 302 eyes with diffuse 
DME with or without CME. At 3-year follow-up, some vision 
improvement was noted only in 15%; visual acuity was unchanged in 
61%, and moderate loss of visual acuity occurred in 24% of eyes. 
Complications can be seen with laser photocoagulation. With time, RPE 
atrophy associated with the laser scars occasionally progresses under the 
fovea causing decreased vision. Also, subretinal fibrosis can develop and 
cause visual loss. 148,161,162.  Thus, grid treatment has limited efficacy for 
diffuse DME.  
Alternative treatments such as intravitreal triamcinolone acetonide 
(IVTA) injections, intravitreal anti-VEGF drugs, and pars plana 
vitrectomy (PPV) in the presence of vitreomacular traction can be tried. 
 
2. Mechanism of Action of Laser Photocoagulation 
The exact mechanism of action of laser photocoagulation- induced 
resolution of DME remains to be unidentified though several hypotheses 
have been put forward. One explanation involves laser-induced 
destruction of oxygen-consuming photoreceptors. Laser photocoagulation 
creates an increase in tissue temperature of 10°C, with heat spreading to 
adjacent RPE cells, photoreceptors, and choriocapillaries. Cell death and 
scarring (involving gliosis and RPE hyperplasia) occurs subsequently. 
The loss of the metabolically active outer tissue enables easier diffusion 
of oxygen from the choriocapillaries into the inner retina. 164,172.  Several 
investigators have demonstrated increased preretinal oxygen partial 
pressure in areas of laser photocoagulation, which Perry and Risco 
explained by the presence of the microvascular repair in the treated zones. 
159,165,166 
 However, Wilson and Green demonstrated choriocapillaris loss 
in areas of argon laser photocoagulation and proposed that increased 
oxygen tension is unlikely to be found in those areas. 171. Also, Wilson 
and coworkers have demonstrated a reduction of the retinal capillary area 
in the zone of laser photocoagulation and proposed that if the total area of 
the abnormal leaking vessels was reduced, the amount of leakage would 
be reduced, which would result in the resolution of the macular edema 
(for a given capillary permeability and hydrostatic pressure). 170  
 
Gottfredsdottir and coworkers studied the diameter of retinal arterioles, 
venules, and their macular branches before and after macular laser 
photocoagulation in eyes with DME. 144 The macular arteriolar branches 
constricted by 20.2% (p <0.001), and the venular branches constricted by 
13.8%. The hypothesis put forward was that the improved retinal 
oxygenation post laser may lead to an autoregulatory vasoconstriction, 
which may improve DME.144  
Another theory proposes that the beneficial effect of laser 
photocoagulation is due to restoration of a new RPE barrier. 41 The 
response of the RPE cells to the injury could be one of the following: in 
relatively small defects (<125 mm), the RPE defect can be filled by cell 
spreading; in larger defects, the cells can proliferate to resurface the area, 
and the RPE can produce cytokines (e.g., TGF-b) that antagonize the 
permeabilizing effects of VEGF. 134,143,156,173. Several complications such 
as full-thickness retinal break, choroidal neovascularization, subretinal 
fibrosis, or symptomatic scotomata have been associated with higher 
energy levels of laser used in the treatment of diabetic macular edema. 
146,147,169
.  These complications can cause symptomatic visual loss. 
Laboratory experiments have shown that RPE defects developing after 
selective subthreshold laser burns, sparing the neural retina but damaging 
RPE cells, are resurfaced by a new population of RPE cells. 
 
 
Laser treatment for maculopathy is generally applied to areas of vascular 
leakage in one of the following patterns: 
● Focal — This is used for circumscribed small areas of macular oedema 
where laser burns are applied to areas of microaneurysms and 
microvascular lesions in the centre of rings of hard exudates. Burns are 
commonly 100 microns in diameter with 0.08–0.1 second duration. 
Longer burn duration causes bigger burns and increased inner retinal 
damage by thermal spread, increased risk of bruchs membrane fractures, 
risk of haemorrhage and later choroidal neovascularization. The power is 
measured in milliwatts and should be kept as low as possible, typically 
starting at around 100 mW. Light burns are therefore used so that the 
laser reaction is just visible as a faint greyish-white reaction — a 
threshold burn. Generally no attempt is made to close retinal blood 
vessels.  
 
 
 
  
 Diagrammatic representation of focal/modified grid laser. 
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● Grid — This is used when there is generalized diffuse macular oedema 
with foveolar involvement, typically using a spot size of 100–200 
microns with a grid pattern of 100–200 burns of 0.08–1.0 s duration 
around the macula.The burns should be of light intensity and placed 
approximately one burn-width apart. If treatment is taken into areas with 
less macular oedema, then the power setting should be reduced. 
Treatment closer than 500 microns from the FAZ should be undertaken 
with caution but is occasionally done as repeat treatment in non-
responsive cases with persistent central oedema. The papillomacular 
bundle area can be safely treated provided there is macular oedema 
within this area, as in this situation the nerve fibre layer will be separated 
from the area of maximum energy uptake within the RPE and thus 
protected from thermal damage. Care should therefore be taken in 
treating ‘dry’ retina within this area and in re-treatments. 
 
● Modified grid is similar to grid settings except the pattern is 
concentrated in a particular sector or sectors of retinal thickening rather 
than a general pattern around the foveal centre. In practice this pattern of 
treatment rather than grid laser is more commonly applied. 
● Treatment was also given in the EDTRS to areas of eccentric capillary 
non-perfusion associated with retinal thickening in the macular area. 
 
Complications of laser treatment 
Para central scotomata are common after treatment close to the foveal 
centre. Patients should be warned that they may notice grey scotomata 
around their central vision for a few days to weeks after treatment. These 
usually however fade with time, but not always. 
Transient worsening of vision can occur due to a transient increase in 
oedema following treatment; again this usually improves. 
Choroidal neovascularization can occur and patients should be 
specifically warned of this complication if they have existing age-related 
macular degeneration (AMD). In this situation the choroidal neovascular 
membrane (CNVM) can actually be just part of the AMD natural history 
and not part of the laser treatment. High intensity small burns should be 
avoided which can rupture bruchs membrane increasing the likelihood of 
choroidal neovascularization. Also it should be noted that CNVM can 
occur spontaneously in patients with severe diabetic macular edema 
(DME). 
 
Sub retinal fibrosis 146,147 can occur, but again this can occur in diffusely 
oedematous maculae as part of the diabetic maculopathy disease course. 
Similarly epiretinal membrane formation can occur. 161 
Laser scar expansion can occur, especially in myopic patients. 162 
Exudate deposition at the foveal centre can occur in extremely 
edematous retinae after treatment, and large exudates close to the fovea 
are also a risk factor. In patients with grossly oedematous maculae, or 
exudates very close to fixation, the option of fractionating the 
maculopathy treatment in a couple of sessions should be considered to try 
and avoid the risk of sub-foveal exudate deposition. 
Increased ischaemia can occur rarely after maculopathy treatment, 
especially in patients with mixed maculopathy. If ischaemia is suspected 
an angiogram should be arranged so that this complication can be 
discussed with the patient if they wish. This is best undertaken with the 
patient looking at the angiogram with the operating clinician. 
Colour vision and contrast sensitivity can be reduced following laser 
and again should be discussed if this is relevant to the patient’s profession 
or hobbies in particular. 
 
Focal laser treatment for diabetic maculopathy clearly works and the 
commonest cause for reduction in vision following laser treatment is 
actually progression in maculopathy rather than deterioration in vision 
secondary to laser. 
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Fernandez et al compared three different laser namely the blue green 
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Figueira et al in a ransomized controlled trial compared subthreshold 
micropulse diode against the green laser in eighty four eyes. They noticed 
no statistically significant difference in all parameters. The parameters 
included visual acuity, contrast sensitivity and retinal thickness. Thus 
they concluded that both lasers had similar efficacy in the treatment of 
CSME.  
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Grid laser photocoagulation in diffuse diabetic macular edema 
Degenring et al evaluated the results of grid photocoagulation in forty one 
eyes of CSME with an average follow up period of 31 weeks. Of the forty 
one eyes they showed five eyes which gained visual acuity. Among the 
others twenty three remained stable whereas 13 lost vision by one line or 
more. They were one of the few studies which actually showed a mean 
drop in visual acuity and recommended that we should evaluate the need 
for grid laser in select cases.  
 
 Ophthalmology. 1997 Sep;104(9):1433-41. 
Diode laser (810 nm) versus argon green (514 nm) modified grid 
photocoagulation for diffuse diabetic macular edema 
Olk RJ et al compared argon green against diode laser for treatment of 
CSME in 171 eyes with a mean follow up of twelve months. They 
reported no statistically significant difference in any of the parameters 
between the two groups. The various parameters used to deteremine the 
efficacy were improvement in vision, drop in vision, reduction in macular 
edema and the number of retreatments required. However they noted an 
important finding that eyes with cystoids macular edema had a poorer 
outcome than patients who did not have any cystoids macular edema. The 
also noted that an associated systemic vascular disease can have an 
adverse effect on the outcome of treatment with either laser.  
 
 Ophthalmology. 1990 Sep;97(9):1101-12; 
 Argon green (514 nm) versus krypton red (647 nm) modified grid 
laser photocoagulation for diffuse diabetic macular edema. 
Olk RJ studied two hundred and twenty five eyes of CSME treated by the 
above mentioned lasers. In a 2 year follow up period they found no 
statistically significant difference among the two lasers. They assessed 
various parameters like visual acuity, reduction in macular edema, 
number of retreatments required and changes in visual field. In all the 
above mentioned parameters there was no difference between the two 
lasers emphasising the fact that both have a similar effect in the treatment 
if diabetic macular edema.   
 
 
AIMS AND OBJECTIVE 
To determine whether the 577 nm yellow laser can provide a better 
treatment outcome when compared with the conventional 532 nm green 
laser for diabetic macular edema.  
Intervention(s) in this Clinical Trial 
• Device: 577 nm yellow laser  
 Laser to be administered at the time of enrollement in the study and 
may be repeated at 16 weeks if there is treatment failure.  
• Device: 532 nm green Frequency doubled Nd:Yag laser  
 Laser to be administered at the time of enrollement in the study and 
may be repeated at 16 weeks if there is treatment failure.  
Groups of the Trial 
• Experimental: 577 nm yellow laser 
• Active Comparator: 532 nm green Frequency doubled Nd:Yag 
laser 
 
 
Outcome Measures for this Clinical Trial 
• Best corrected visual acuity by logarithm of the minimum angle of 
resolution (LogMAR) compared to pre laser vision and vision at 4 
months post laser 
•Macular thickness measured by optical coherence tomography (OCT) 
comparing pre laser macular thickness and thickness measured by OCT at 
4 months post laser 
  
MATERIALS AND METHODS 
A sample of 71 eyes from 54 patients, 36 males and 18 female 
patients between 44 to 76 years of age, who fit the criteria for the study 
were included in the study during the recruitment period between January 
2011 to December 2011 and the follow up period extended upto June 
2012. The total study duration was of 18 months.  
INCLUSION CRITERIA: 
• Age >= 18 years. 
 Diagnosis of diabetes mellitus (type 1 or type 2) or a documented 
diabetic who is currently using insulin or oral hypoglycemic agents 
 DIAGNOSIS OF CSME as documented clinically by a 
experienced retinal surgeon along with proof of its presence in 
OCT.  
EXCLUSION CRITERIA: 
 Patient having significant renal disease i.e. a case of chronic kidney 
disease that mandates regular dialysis or kidney transplant.  
 An uncontrolled systemic hypertensive with a systemic Blood 
pressure > 180/110. 
 The following exclusions apply to the study eye only (i.e., they 
may be present for the non study eye): 
 Vitreo macular traction as diagnosed by OCT or clinically 
 Concurrent proliferative diabetic retinopathy. 
 Associated ocular morbidity that would preclude restoration of 
visual acuity even after resolution of macular edema (e.g., foveal 
atrophy, subfoveal hard exudates, pigment abnormalities, 
significant macular ischemia caused be vein occlusions or diabetes, 
optic atrophy or other optic nerve head disorders). 
 A coexistent ocular condition is present (other than diabetic 
retinopathy) that by its natural course might affect macular edema 
or alter visual acuity during the course of the study (e.g., vein 
occlusion, uveitis or any ocular inflammatory disease, epiretinal 
membrane, neovascular glaucoma, etc.). 
 Substantial cataract that is likely to be decrease visual acuity by 3 
lines or more  
 History of focal or grid macular photocoagulation within six 
months prior to enrolment.  
 History of use of periocular or intraviteral steroids within six 
months prior to enrolment. 
 History of having been administered intravitreal ANTI VEGF 
agents within six months prior to enrolment.   
 History of panretinal (scatter) photocoagulation (PRP) prior to 
enrollment.  
 History of major ocular surgery within prior 6 months or 
anticipated within the next 6 months. 
 Patients who will be unable to come for a follow up visit at 4 
months post laser.  
Sample Size Calculation: As there was no previous published reports 
on the comparative efficacy of 532nm frequency doubled Nd:Yag green 
laser versus the 577nm solid state yellow laser, comparative analysis of 
other lasers were sought and sample size was brought about by the 
number of cases which fit the inclusion and exclusion criteria within the 
recruitment period of one year from January 2011 to December 2011. 
 
 
 
METHODOLOGY 
A data sheet was attached to the case sheets of the patients enrolled 
in the study. The data sheet contains a detailed patient history regarding 
the duration of defective vision, the duration of diabetes mellitus, history 
of prior ocular disease, history of any surgery or procedure performed in 
the study eye.  
The visual acuity at enrolment was recorded using a Snellen’s visual 
acuity chart. The Snellen’s visual acuity was then converted to logarithm 
of the minimum angle of resolution (LogMAR) scale at the time of 
statistical analysis.  
Patient then undergoes a detailed slit lamp examination and the anterior 
segment findings including lens status was recorded.  
A thorough fundus examination was done by a retina specialist and the 
diabetic Retinopathy was graded according to the ETDRS Classification 
of diabetic retinopathy and the presence of clinically significant macular 
edema was recorded.  
Basic blood investigations including postprandial blood sugar, 
Hemoglobin A1C, Blood Urea And Serum Creatinine was done for all 
patients.  
A fundus photograph of the patient was taken and a Fundus fluoroscein  
angiography was done after obtaining a physician s fitness.  
A Ocular coherence tomography of the study eye was performed using 
Zeiss Cirrus SD-OCT and the foveal and/or para foveal thickness 
depending on the area and extent of involvement was noted.  
The patient was then randomized by a table of random numbers and 
assigned to either the experimental group (577nm yellow laser) or into 
the active comparator group (532nm green laser).  
Informed consent was obtained from the patient. Pupils were fully dilated 
using 1% tropicamide eye drops. Topical anaesthesia was attained by 
using 2% xylocaine, 3-4 application before the procedure. Volk contact 
lenses were used for magnifications, controlling the globe and laser 
delivery. The 532 nm green laser was delivered using the Iridex laser 
delivery system. The 577nm yellow laser was administered using the 
Iridex laser delivery system.  The laser power was titrated according to 
the extent of thickness of the macular edema. The number of spots was 
also varied between the patients according to the area of involvement of 
the macula. The duration of the laser spot delivary was fixed at 0.1 
second. The laser was administered either as a focal laser for focal 
macular edema or as a modified grid laser for diffuse macular edema. The 
modified grid pattern was given as a C pattern with laser burns given in 2 
-3 rows superior, temporal and inferior to the fovea with a minimum of 
500 microns distance away from the centre of the fovea sparing the 
papillomacular bundle. 
The patients were then asked to review at 4 months post laser. At follow 
up the visual acuity was recorded with Snellen’s visual acuity chart. A 
detailed slit lamp and 90 D fundus examination was done and the macular 
thickness (foveal or parafoveal) using the Carl Zeiss Spectral Domain 
OCT was recorded. In case of worsening of macular thickness a repeat 
laser of the same type as the one administered in the first visit was 
considered at 4 months post laser to improve the treatment outcome.  
 
 
 
 
 
 
 
RESULTS AND ANALYSIS 
A prospective randomized study was done on 71 eyes of 54 
patients whose visual acuity and macular thickness by OCT was recorded 
prior to and 4 months after application of laser,  conducted at the Vitreo 
Retina Clinic, Aravind Eye Hospital, Madurai between Jan 2011 to June 
2012.  
Statistical analysis 
The Statistical analysis was performed using STATA 11(Stata Corp TX 
College Station USA).  
The continuous variables are described as Mean ± Standard deviation, 
and the categorical variables are described as frequency and percentage.  
Student Independent sample t-test was used for age, HbA1C and power 
for find the statistical significance between  green and yellow laser. 
 Wilcoxon sign rank was used for Log MAR Visual acuity, Foveal and 
parafoveal measurements of Baseline and follow up (four months) were 
compared and used the students paired t-test.  P<0.05 is considered as 
statistically significant 
 
1. Age: 
The age of the patients in the two arms of the study ranged between 44 to 
76 years.  
The mean age of patients in the Green laser group was 56.94 years. 
The mean age of patients in the yellow laser group was 56.13 years. 
2. Sex Ratio: 
 
Male 
Female 
Total 
 
There were 36 males(66%) and 18 female patients(34%) distributed 
among the two arms of the study. 
Frequency Percentage 
36 66 
18 34 
54 100 
 
 
 
 
3. Number of eyes in each group:
The eyes of individual patients were randomized to each group by a table 
of random numbers and there were 34 eyes (48%) in the green laser 
group and 37 eyes (52%) in the yellow laser group. 
 
Green
Yellow
Total 
 
 
 
52 %
 
 
Frequency Percentage 
 34 48 
 37 52 
71 100 
48 %
Green
Yellow
 
4. Hemoglobin A1C: 
Hemoglobin A1c was measured in all 54 patients in the two groups.  
The mean measured HbA1c in the green laser group was 6.81 with a 
standard deviation of 0.99. 
The mean measured HbA1c in the yellow laser group was 6.70 with a 
standard deviation of 1.56. 
 
5. Diabetic Retiopathy Status: 
All 54 patients either had moderate or severe NPDR.  
30 of the 71 eyes had moderate NPDR with 14 eyes in the green laser 
group and 16 eyes in the yellow laser group.  
The remaining 41 eyes of the 71 eyes had Severe NPDR with 20 eyes in 
the green laser group and 21 eyes in the yellow laser group.  
 
 
 
 
Diabetic retinopathy status:
 Green
Mild -- 
Moderate 14 
Severe 20 
Total 34 
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6. Visual Acuity: 
The visual acuity was recorded by Snellen s Visual Acuity chart at a 
distance of 6 metres, at baseline, prior to application of laser and was 
recorded again at 4 months review. The Visual acuity was then converted 
to the Standard LogMar scale prior to statistical analysis.  
Visual Acuity 
 Baseline 4 Months (After 
Laser) 
P-Value 
 Median (IQR) Median (IQR)  
Green 0.18 (0.48) 0.18(0.18) 0.002 
Yellow 0.3(0.48) 0.18(0.18) <0.001 
 
The Median Visual acuity at baseline in the Green laser group was 
0.18(0.48) and 0.3(0.48) in the yellow laser group as measured by 
LogMar scale.  
At 4 months after laser the median visual acuity in the green laser group 
had improved to 0.18 which was statistically significant with a p value of 
0.002.  
At 4 months after laser the median visual acuity in the yellow laser group 
had improved to 0.18 which was statistically significant with a p value of 
<0.001.  
There was however no statistically significant difference between the 
degree of improvement of visual acuity between green and yellow laser. 
Thus the green and yellow laser had no difference in the efficacy of 
improvement of visual acuity post laser.  
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There are 3 outliers in the above graph. They are the 3 patients who 
required repeat laser at 4 months post laser due to unsatisfactory 
improvement or deterioration in any one of the outcome variables namely 
visual acuity and measured macular thickness on OCT. 2 of these patients 
belonged to the green laser group and 1 patient from the yellow laser 
group required repeat laser at 4 months post laser. All three patients 
showed significant improvement in the macular thickness as measured by 
OCT at 4 months post repeat laser.  
 
7. Power setting used in each laser system: 
The mean power of laser used in the green laser group was 112mW with 
a standard deviation of 18mW.  
The mean power of laser used in the yellow laser group was 111mW with 
a standard deviation of 21 mW.  
 
 
 
 
 
8. Optical Coherence Tomography Results:
8a. Foveal: 
 Baseline
 Mean ± SD
Green 306.21 ± 133 
Yellow 308 ± 131
The mean measured foveal thickness by OCT in the green laser group 
was 306.21 microns with a standard deviation of 133 microns. At 4 
months post laser the foveal thickness had decreased to 254.44 microns 
with a standard deviation of 105.27 microns. This sh
significant difference in the improvement in the macular thickness at 4 
months post green laser with a p value of <0.001. 
0
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P-Value
 Mean ± SD  
 254.44 ± 105.27 <0.001
 218 ± 66 <0.001
owed a statistical 
 
4 Months 
254
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218
Mean OCT Foveal
 
 
 
 
Green
Yellow
The mean measured foveal thickness by OCT in the yellow laser group 
was 308 microns with a standard deviation of 131 microns. At 4 months 
post laser the foveal thickness had decreased to 218 microns with a 
standard deviation of  66 microns. This showed a statistical significant 
difference in the improvement in the macular thickness at 4 months post 
yellow laser with a p value of <0.001.  
8.b Parafoveal thickness comparison between pre and post laser 
using OCT 
 Baseline 4 Months (After Laser) P-Value 
 Mean ± SD Mean ± SD  
Green 417 ± 75 308 ± 72 <0.001 
Yellow 422.35 ± 65  276 ± 41 <0.001 
 
The mean measured parafoveal thickness by OCT in the green laser 
group was 417 microns with a standard deviation of 75 microns. At 4 
months post laser the parafoveal thickness had decreased to 308 microns 
with a standard deviation of  72 microns. This showed a statistical 
significant difference in the improvement in the parafoveal macular 
thickness at 4 months post green laser with a p value of <0.001.  
The mean measured parafoveal thickness by OCT in the yellow laser 
group was 422.35 microns with a stand
months post laser the parafoveal thickness had decreased to 276  microns 
with a standard deviation of  41 microns. This showed a statistical 
significant difference in the improvement in the macular thickness at 4 
months post yellow laser with a p value of <0.001.
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9. Comparison of measure of reduction in foveal thickness after 
using green and yellow laser: 
9A. Foveal thickness 
 Green Laser Yellow  
Foveal    
% of Reduction 17% 29% 0.135 
 The green laser caused a 17% reduction in foveal thickness over a period 
of 4 months. In the same time interval yellow laser showed a slightly 
better efficacy with an improvement in foveal thickness by 29%. But the 
difference in the reduction of foveal thickness between the two laser was 
not statistically significant with a p value of 0.135.  
9B. Parafoveal thickness 
 Green Yellow P-
Value 
Parafoveal    
% of 
Reduction 
26% 35% 0.411 
 
The green laser caused a 26% reduction in parafoveal thickness over a 
period of 4 months. In the same time interval yellow laser showed a better 
efficacy with an improvement in parafoveal thickness by 35%. But the 
difference in the reduction of parafoveal thickness between the two laser 
was not statistically significant with a p value of 0.411.  
  
DISCUSSION 
ETDRS firmly established the role of laser in the treatment of diabetic 
macular edema 173. Over the years several lasers have been developed 
each of which have shown different levels of efficacy in treating diabetic 
macular edema. Despite the development of newer agents like intra 
vitreal triamcinolone and Anti VEGF drugs, laser continues to remain the 
definitive and gold standard treatment of diabetic macular edema.  
Our Study included a total of 71 eyes of 54 patients who fit the inclusion 
criteria between the period January to December 2011. This is 
comparable to other studies where they have compared the efficacy of 
two laser groups in treating diabetic macular edema. A study by Fugueira 
et al 181 comparing the efficacy of micropulse diode laser with 
conventional green had 84 eyes from 53 patients. Another study by 
Karacorlu et al(2) comparing the efficacy of argon green with dye yellow 
laser had a total number of 85 eyes.  
The age range of the patients included in our study was from 44 to 76 
years with the mean age in the green laser group being 56.94 years and 
that in the yellow group was 56.13 years with a very similar age 
distribution of patients in the two groups. All the patients in our study 
were Type II diabetics. A study by JK Lutrull et al 182 had an age range of 
42 to 90 years with the mean age being 56 years. Our study comprised of 
36 males and 18 females with a sex ratio of 2:1.  
It has been well established that HbA1C has a definitive diagnostic role to 
play in the control of diabetes of mellitus and patients with very high 
values of HbA1C are at risk of progression of Diabetic Retinopathy 
despite adequate laser treatment. So a cut off value of HbA1C of 10% 
was taken in our study. This value was similar to the criteria taken in 
previous comparative studies by Laursen et al 180 and Sivaprasad S et al 
182
. In our study we had patients with fairly controlled diabetes with the 
mean HbA1C in the green group being 6.81% and that in the yellow 
group being 6.70%.  
The patients were randomized in the two groups and after consent for 
laser was taken underwent laser as assigned in the two groups.  
The exact mechanism of grid laser photocoagulation is unknown. 
Electron microscopic studies in monkeys and rabbits were the basis for 
suggesting that the mechanism involved in photocoagulation might be an 
opening up of new pathways by disrupting the retinal pigment epithelial 
diffusion barrier, thus allowing the egress of fluid from the retina or 
subretinal spaces across the retinal pigment epithelium as evidenced by 
the passage of tracer material from the choriocapillaries into the 
subretinal space. 174,175,176  
Others suggested that the mechanism of grid photocoagulation might be 
“photocoagulation debridement of disordered retinal pigment epithelium” 
ultimately leading to removal of the disordered or sick retinal pigment 
epithelial cells and replacement by a young more vigorous population of 
cells with better RPE pumping activity 177. Another possible explanation 
is that the laser may directly act on the leaking retinal microaneurysms 
causing their closure by photocoagulation and preventing further leakage. 
The lasers are absorbed by the melanin and xanthophylls pigments in the 
retinal pigment epithelium for their action to occur 179. Both green and 
yellow laser have low absorption by melanin pigments(1). The distinct 
advantage of yellow laser is that it has almost no affinity towards macular 
xanthophylls pigments and thus causes minimal phototoxicity. It also has 
a high affinity for oxy haemoglobin(1) which helps in focal laser as the 
yellow wavelength is absorbed by the oxy haemoglobin in the retinal 
microaneurysms leading to their closure.   
The baseline visual acuity across the two groups as measured by LogMar 
Visual Acuity scale was 0.18 in the green group and 0.3 in the yellow 
group. At 4 months post laser the visual acuity was stable or better in 68 
of the 71 eyes. Only 3 eyes had a decrease in visual acuity necessitating 
repeat laser treartment. Thus 94.4% of patients had a stable or better 
visual acuity than at baseline. The patients from both laser groups had a 
statistically significant improvement in vision post laser treatment.  The 
results produced in terms of stable vision and re treatments required were 
similar to the study by JK Lutrull et al(182) where they have shown 
statistically significant improvement in vision. In the study by Karacorlu 
et al 2 there was a drop in vision in 12 of 85 eyes after using either argon 
green or dye yellow laser.  
No statistically significant difference was noted in the outcome of visual 
acuity between green and yellow laser. Other reports too by Karacorlu et 
al 2  showed no additional benefit of dye yellow laser over conventional 
green laser in relation to visual outcome. A study by Fuguiera et al181  
also showed no significant difference in the outcome of visual acuity 
when two laser of different wavelengths were used to treat diabetic 
macular edema.  
The power of the laser setting to cause laser photocoagulation of mild 
intensity in our study was 112mW in the green laser group with a 
standard deviation of 18mW and in the yellow laser group was 111mW 
with a standard deviation of 21 mW. There was no statistically difference 
between the two groups in the amount of power required to treat diabetic 
macular edema. A study by Karacorlu et al 2 says that they required 20% 
less power in the dye yellow laser group as compared to the argon green 
laser group during grid photocoagulation.  
 On measurement of macular thickness on Optical Coherence 
Tomography showed a statistically significant decrease in the amount of 
macular edema both foveal and perifoveal after treatment with laser in 
both the treatment groups. 
The green laser caused a 17% reduction in foveal thickness over a period 
of 4 months. In the same time interval yellow laser showed a slightly 
better efficacy with an improvement in foveal thickness by 29%. But the 
difference in the reduction of foveal thickness between the two laser was 
not statistically significant with a p value of 0.135. The perifoveal 
thickness also reduced significantly with a reduction of 26% in the green 
laser group and further reduction of 35% in the yellow laser group. 
Though both lasers showed very significant decrease in perifoveal 
thickness with a slightly better improvement in the yellow laser group, 
this difference was not statistically significant.  
No untoward complications like loss of central vision, choroidal 
neovascularisation, subretinal fibrosis, exudates migration to the fovea 
was found during the duration of the study and follow up.  
  
LIMITATIONS OF THE STUDY 
1. Though yellow laser showed some advantage over the green laser 
in reducing the quantum of macular edema on OCT, the size of the 
study was not enough to produce a statistically significant 
difference.  
2. The use of more objective measures like microperimetry which is 
not available at our institute would help in detecting the extent of 
macular scotomata caused by the laser and help in assessing the 
quantity of improvement in vision.  
3. Other measures of vision like contrast sensitivity and quantitative 
measures of colour vision like Fransworth Munsell 100 hue test 
could bring out subtle differences.  
4. A longer follow up period is required to test the stability of visual 
improvement produced by the yellow laser and also to look for 
long term complications.  
5. This study did not include patients who had been administered 
intravitreal triamcinolone and intravitreal Anti VEGF drugs. A 
more comprehensive study to compare the laser uptake and 
efficacy following this intravitreal agents is called for.  
6. This study also did not compare the outcome of individual lasers in 
treating spongiform against cystic edema as shown by OCT.  
CONCLUSION 
The study emphatically reiterates the role of laser alone in the treatment 
of diabetic macular edema in carefully chosen cases. In well controlled 
diabetics laser continues to remain the gold standard in the treatment of 
diabetic maculopathy. No statistically significant advantage was shown 
for the 577nm solid state yellow laser over the 532nm frequency doubled 
Nd:Yag laser in reducing macular edema but a positive trend was shown 
which needs a larger study group and a more prolonged follow up to 
detect accurate and more minute differences.  
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COMPARISON OF COMMONLY USED LASER 
WAVELENGTHS 
CHARACTERISTICS* ARGON 
BULE – 
GREEN 
(488 nm) 
ARGON 
GREEN 
(514 nm) 
DYE 
YELLOW 
(577 nm) 
KRYPTON 
RED (647 
nm) 
Hemoglobulin 
absorption 
80% 78% 98% 5% 
Macular xanthophylls 
Absorption # 
59% 11% 0% 
 
0% 
Melanin  
(RPE) # absoption 
50% 45% 40% 35% 
Transmission through 
ocular media Δ 
29% 35% 47% 50% 
 
*All percentages given are approximations 
#  Depends on light versus dark  fundi. 
 Δ Depends on age. 
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10 Yellow Salahudeen 60 M Kollam, Kerela 3109224 6.4 RE R 6/12p 6/12 wnl Re: Mod NPDR CSME 423 120 100 38 RE 6/6p 6/6 226
11 Green Dharmarajan 65 M Santhaipettai, Madurai 3168421 6.9 RE Re: 6/24 6/24 lens changes Re: Severe NPDR CSME with CME PVD 660 120 100 42 RE 6/18 6/18 480
12 Yellow Maragatham 40 F Nethaji Road, Madurai 3106807 7.2 RE Re 6/9p 6/9 Wnl BE: Mod NPDR/CSME 188 399 160 100 11 RE 6/9 6/9 186 348
13 Yellow Suganthan 61 M Varkala, Trivandrum 3133977 8.3 LE LE 6/12 6/12 LC LE: SEVERE NPDR/CSME 334 90 100 25 RE 6/9p 6/9 214
14 Yellow Subramnaniam 63 M jayanthi Nagar, Madurai 3156654 7.9 RE re 6/12p 6/12 wnl BE: Mod NPDR/CSME 311 511 150 150 47 RE 6/9 6/9 220 344
15 Yellow Aysha Beevi 56 F Thasiladar Nagar, Madurai 3167633 8.4 LE LE 6/18 6/18 wnl BE: Mod-Severe NPDR/CSME 309 482 120 100 24 LE 6/12 6/12 190 312
16 Yellow Premchand 50 M Trivandrum 3190307 8.6 RE re 6/9 6/9 wnl BE: Mod-Severe NPDR/CSME 346 120 100 42 RE 6/9 6/9 391 110, 100, 51 270u
17 Yellow Rabiyammul 72 F Vilachery, Madurai 3193007 5.2 RE re 6/24p 6/24 ns II BE: Mod-Severe NPDR/CSME 296 400 140 120 41 RE 6/9 6/9 170 320
18 Green Kunhaysha 70 F Vadakara, Kozhikode 3204785 6.4 LE le 6/12 6/12 lc BE: Severe NPDR/CSME 207 223 150 100 49 LE 6/9 6/9 180 112
19 yellow Indira 56 F Kandalloor, Allepey 3208489 8.9 RE re: 6/36 6/36 lc BE: Severe NPDR/CSME 630 100 100 60 RE 6/18 6/18 415
20 yellow Indira 56 F Kandalloor, Allepey 3208489 8.9 LE le: 6/6p 6/6 lc BE: Severe NPDR/CSME 188 328 100 100 34 LE 6/6 6/6 160 265
21 yellow Seshan 52 M Simmakkal, Madurai 2906835 8.1 RE re: 6/36p 6/36 early imc BE: Severe NPDR/CSME 603 120 100 102 RE 6/36 6/36 384
22 Green Kalaiselvi 48 F Annamalai Nagar, Tanjore 3143412 6.6 RE re 6/18 6/18 imc be: severe npdr/csme 319 100 100 29 RE 6/9 6/9 250
23 Green Kalaiselvi 48 F Annamalai Nagar, Tanjore 3143412 6.6 LE le 6/24 6/24 imc be: severe npdr/csme 375 120 100 42 LE 6/18p 6/18 363
24 Green Seshan 52 M Simmakkal, Madurai 2906835 8.1 LE le: 6/12p 6/12 early imc BE: Severe NPDR/CSME 415 130 100 94 LE 6/12 6/12 319
25 Yellow Abdul Wahab 65 M Mudukulathur, Ramanathapuram 3128738 6.2 LE le: 6/9 6/9 wnl Be: Mod NPDR/CSME 248 453 140 100 46 LE 6/9p 6/9 186 290
26 Yellow Anthony P.C. 74 M Ramakkal Medu P.O., Idukki, Kerela 3214535 5.5 RE re: 6/12p 6/12 early imc Be:Severe NPDR/CSME 363 150 100 61 RE 6/12 6/12 250
27 green Karishma Begum 55 F Sattankulam, Ramanathapuram 3184299 5.0 LE le 6/12 6/12 lc LE: Mod npdr csme 255 439 110 100 40 LE 6/9 6/9 210 294
28 green Kesari das 48 F Thiruvarambu, Kanyakumari 3017220 8.0 RE 6/6p 6/6 lc BE: Mod-Severe NPDR/CSME 241 391 140 100 36 le 6/6 6/6 160 265
29 green Ayyasamy 73 M Valangaiman, Thiruvarur 3204341 8.6 RE re: 6/18p 6/18 pciol BE: Severe NPDR/CSME 625 110 100 34 re 6/9p 6/9 600 100, 100, 41 390u
30 Yellow Paneer Selvam 58 M Virudhunagar 3235638 6.4 RE re 6/18 6/18 wnl BE: Severe NPDR/CSME 410 90 100 42 Re 6/9p 6/9 240
31 Yellow Durairaj 42 M Ramanathapuram 3128742 5.8 RE re 6/6p 6/6 wnl Re: Mod Npder with CSME 640 100 100 28 RE 6/6 6/6 218
32 Yellow Anthony P.C. 74 M Ramakkal Medu P.O., Idukki, Kerela 3214535 5.5 LE le: 6/18 6/18 early imc BE: Severe NPDR/CSME 420 150 100 52 LE 6/12 6/12 242
33 Yellow Chandra Devi 50 F Mettupatti, Vadipatti 2218268 6.9 RE re: 6/6p 6/6 wnl Be: Mod NPDR/CSME 170 327 130 100 84 RE 6/6 6/6 168 244
34 green Lakshmanan 40 M Thiruppalai, Madurai City 3235646 6.4 RE re: 6/6 6/6 wnl Be: Mod NPDR/CSME 199 383 100 100 53 RE 6/6 6/6 180 242
35 Yellow Chandra Devi 50 F Mettupatti, Vadipatti 2218268 6.9 LE le: 6/6p 6/6 wnl Be: Mod NPDR/CSME 327 431 130 100 72 RE 6/6 6/6 217 311
36 green Ayyanar 52 M Vellipattinam, Ramanathapuram 3240581 6.9 LE le: 6/9 6/9 lens changes LE: Mod npdr csme 184 440 120 100 78 le 6/6p 6/6 182 360
37 green Karuppaiah 57 M Sekkalai, Karaikudi 2571485 7.1 RE re:6/9 6/9 lc re: Mod - Severe NPDR/CSME 327 519 120 100 48 Re 6/6 6/6 240 410
38 yellow Karuppaiah 57 M Sekkalai, Karaikudi 2571485 7.1 RE le:6/9p 6/9 lc le: Mod - Severe NPDR/CSME 237 455 100 100 62 Re 6/6 6/6 186 270
39 Yellow Abdul Azeez 43 M Malapuram, Kerala 3235639 7.4 RE re: 6/6p 6/6 WNL BE: Severe NPDR/CSME 245 480 120 100 51 Re 6/6 6/6 211 326
40 Yellow Ponnammal 66 F Aruppukottai, Virudhunagar 3174419 5.6 RE re: 6/12p 6/12 pciol re: Mod - Severe NPDR/CSME 141 430 100 100 135 Re 6/9 6/9 136 260
41 Yellow Jose K.J 59 M Kottayam 3253919 7.2 RE re: 6/24 6/24 early pscc re: Disc pallor/ Severe NPDR/CSME 163 435 80 100 80 RE 6/18 6/18 156 230
42 Yellow Ramalingam 63 M Samiyarpatti, Athoor, Dindigul 3130521 5.8 RE re: 6/9p 6/9 WNL re: Mod - Severe NPDR/CSME 210 396 110 100 46 RE 6/9 6/9 186 260
43 green Jose K.J 59 M Kottayam 3253919 7.2 LE le: 6/6p 6/6 early pscc LE: severe npdr csme 151 472 100 100 64 le 6/6 6/6 148 302
44 green Narayanasamy 70 M Sayanethal, Virudachalam 3257358 6.5 LE le: 6/6p 6/6 pciol LE: Mod npdr csme 225 407 100 100 61 le 6/6 6/6 210 390
45 Yellow Sandavaliyan 57 M Vasantha Nagar, Madurai 3258577 7.4 RE re: 6/6 6/6 lc re: severe npdr csme 156 326 100 80 39 re 6/6 6/6 151 216
46 green Sandavaliyan 57 M Vasantha Nagar, Madurai 3258577 7.4 LE le: 6/6p 6/6 lc LE: severe npdr csme 170 348 100 80 47 le 6/6 6/6 165 254
47 yellow Sivakumar 60 M Aruppukottai, Virudhunagar 2987762 6.9 LE le: 6/12p 6/12 pciol LE: Mod npdr csme 320 120 100 46 le 6/9 6/9 236
48 Yellow Rajamani 60 F K.K.Nagar, Madurai 2542384 8.4 LE le: 6/24 6/24 pciol LE: Mod npdr csme 215 326 80 100 24 le 6/12p 6/12 170 214
MATER CHART 
49 Yellow Rengaiah 58 M Devapatti, Pudukottai fh-1167618 5.4 LE le: 6/12p 6/12 lc LE: severe npdr csme 163 387 110 100 28 le 6/9 6/6 148 217
50 green Karuppaiah 57 M Sekkalai, Karaikudi 2571485 8.3 LE le: 6/9p 6/6 early imc LE: Mod npdr csme 412 487 80 100 51 le 6/9 6/9 254 311
51 Yellow Vellaisamy 60 M Kumaran Thirunagar, Dindigul 3169450 5.6 LE le: 6/6p 6/6 wnl LE: Mod npdr csme 227 455 90 100 32 le 6/6p 6/6 203 264
52 green Ravichandran 53 M Philomina Nagar, Tanjore 2910825 6.2 LE le: 6/6p 6/6 pciol LE: severe npdr csme 187 380 150 80 22 le 6/6 6/6 166 224
53 green Chandra 58 F Visaloor, Tanjore 3321651 7.4 RE RE: 6/9 6/6 lens changes re: severe npdr csme 160 295 160 100 34 le 6/9 6/9 164 270
54 green Ayyammal 51 F Pillayar Koil street, sholavandan, vadiapptty3325541 5.6 RE re:6/6 6/6 lc re: Mod  NPDR/CSME 286 380 120 100 70 RE 6/6 6/6 210 286
55 green Ayyammal 51 F Pillayar Koil street, sholavandan, vadiapptty3325541 5.6 LE le: 6/6 6/6 lc LE: Mod npdr csme 490 110 100 60 le 6/9 6/9 360
56 Yellow Palanisamy 56 M Dharapuram 2923207 6.0 RE re: 6/6 6/6 wnl RE: mod npdr csme 185 356 100 100 34 re 6/6 6/6 160 267
57 green Palanisamy 56 M Dharapuram 2923207 6.0 LE le: 6/6 6/6 wnl LE: severe npdr csme 165 360 110 100 42 le 6/6 6/6 155 282
58 green Sivaranjini 57 M Vellipatinam, Ramnad 3251256 8.5 LE le: 6/12p 6/12 lens changes LE: Mod npdr csme 184 426 120 100 75 le 6/9 6/9 178 284
59 green Muthuvel 60 M Boopalathi Street, Rajapalayam 3237426 6.4 Re re: 6/9 6/9 lens changes re: Mod - Severe NPDR/CSME 144 378 120 80 60 RE 6/9 6/9 140 280
60 green Thilakavatthi 57 F Pudur, Madurai 3248231 7.9 RE re" 6/12p 6/12 WNL re: severe npdr csme 311 446 110 100 64 RE: 6/9 6/9 236 312
61 Yellow Pandiaraj 43 M Thirunagar, Dindigul 3269455 6.1 Re Re 6/6p 6/6 WNL RE: mod npdr csme 241 466 90 100 66 RE: 6/6 6/6 214 316
62 Yellow Narayanan 68 M KK Nagar, Madurai 3256481 7.2 RE Re: 6/12p 6/12 pciol re: severe npdr csme 211 383 100 100 56 Re: 6/9 6/9 182 226
63 green Thasleema Begum 66 F Kollam, Kerela 3168426 8.2 RE Re: 6/18 6/18 pciol re: severe npdr csme 362 480 100 100 42 Re: 6/9 6/9 264 344
64 Yellow Thasleema Begum 66 F Kollam, Kerela 3168426 8.2 LE Re: 6/18p 6/18 pciol LE: severe npdr csme 341 466 90 100 38 Le: 6/12 6/12 216 260
65 Yellow Jeyakumar 46 M Chockikulam, Madurai 3361412 5.8 RE Re: 6/9p 6/6 WNL RE: mod npdr csme 260 364 110 100 58 Re: 6/6 6/6 204 268
66 green Jeyakumar 46 M Chockikulam, Madurai 3361412 5.8 LE le: 6/9 6/9 WNL LE: Mod npdr csme 221 312 120 100 64 Le: 6/6p 6/6 208 256
67 green K.S.Raju 58 M Thillai Nagar, Trichy 3352489 7.1 LE LE 6/24 6/24 lens changes LE: Mod - Severe NPDR/CSME 382 471 110 100 38 LE: 6/18p 6/18 368 454 120, 100, 42  320u
68 green Joseph K.J 68 M Kottayam 3331624 7.5 RE Re: 6/12p 6/12 pciol re: severe npdr csme 318 512 110 100 54 Re: 6/9 6/6 246 390
69 green Joseph K.J 68 M Kottayam 3331624 7.4 LE LE: 6/18p 6/18 pciol LE: severe npdr csme 346 490 120 100 62 LE: 6/12 6/12 260 344
70 Yellow Manickam 42 M Vellakoil 3334296 6.9 RE RE 6/18 6/18 WNL re: severe npdr csme 324 542 100 100 48 re: 6/9 6/9 218 304
71 Yellow Manickam 42 M Vellakoil 3334296 6.9 LE le: 6/12p 6/12 WNL LE: severe npdr csme 352 512 90 100 52 le: 6/6p 6/6 232 268
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1 Yellow Velayudhan 58 M Ezhachery, Kottayam 3087774 6.5 RE R-6/9 6/9 early imc R:Mod NPDR/CSME 496 100 100 25 RE 6/9 6/9 284
2 Green Savithri 55 F Mattaparai, Dindigul 3098148 5.8 RE R-6/18 6/18 early IMC RE: Mod NPDR/CSME 243 507 90 100 55 RE 6/9 6/9 210 380
3 Green Savithri 55 F Mattaparai, Dindigul 3098148 5.8 LE LE - 6/9p 6/9 Early IMC LE: Mod NPDR/CSME 235 455 90 100 32 LE 6/9 6/9 216 340
4 Yellow Dhanapackiam 52 F Kambilampatti, Dindigul 3098234 6.8 RE R-6/12P 6/12 lens changes RE: Mod-Severe NPDR/CSME Hard Exudate plaque-parafoveal290 110 100 111 RE 6/9 6/9 171
5 Green Dhanapackiam 52 F Kambilampatti, Dindigul 3098234 6.8 LE L-6/6P 6/6 lens changes LE: Mod NPDR/CSME 452 100 100 81 LE 6/6p 6/6 239
6 Green Shahul Hameed 62 M Athirampatinam, Tanjore 3065765 7.2 RE R - 6/18 6/18 IMC (PSCC) RE- severe NPDR/CSME 370 100 100 39 RE 6/12 6/12 254
7 Green Manickam 70 M Athoor, Dindigul 3078366 4.9 LE le - 6/6p 6/6 wnl L: ModNPDR/CSME 484 110 100 25 LE 6/6 6/6 420
8 Yellow Ramamoorthy MS 42 M Aruuppukottai, Virudunagar 3100503 5.5 RE RE 6/24 6/24 wnl RE: severe npdr/csme 469 90 100 62 re 6/9 6/9 310
9 Green Ramamoorthy MS 42 M Aruuppukottai, Virudunagar 3100503 5.5 LE LE 6/24p 6/24 WNL LE: severe npdr/csme 647 70 100 21 re 6/12 6/12 416
10 Yellow Salahudeen 60 M Kollam, Kerela 3109224 6.4 RE R 6/12p 6/12 wnl Re: Mod NPDR CSME 423 120 100 38 RE 6/6p 6/6 226
11 Green Dharmarajan 65 M Santhaipettai, Madurai 3168421 6.9 RE Re: 6/24 6/24 lens changes Re: Severe NPDR CSME with CME PVD 660 120 100 42 RE 6/18 6/18 480
12 Yellow Maragatham 40 F Nethaji Road, Madurai 3106807 7.2 RE Re 6/9p 6/9 Wnl BE: Mod NPDR/CSME 188 399 160 100 11 RE 6/9 6/9 186 348
13 Yellow Suganthan 61 M Varkala, Trivandrum 3133977 8.3 LE LE 6/12 6/12 LC LE: SEVERE NPDR/CSME 334 90 100 25 RE 6/9p 6/9 214
14 Yellow Subramnaniam 63 M jayanthi Nagar, Madurai 3156654 7.9 RE re 6/12p 6/12 wnl BE: Mod NPDR/CSME 311 511 150 150 47 RE 6/9 6/9 220 344
15 Yellow Aysha Beevi 56 F Thasiladar Nagar, Madurai 3167633 8.4 LE LE 6/18 6/18 wnl BE: Mod-Severe NPDR/CSME 309 482 120 100 24 LE 6/12 6/12 190 312
16 Yellow Premchand 50 M Trivandrum 3190307 8.6 RE re 6/9 6/9 wnl BE: Mod-Severe NPDR/CSME 346 120 100 42 RE 6/9 6/9 391 110, 100, 51 270u
17 Yellow Rabiyammul 72 F Vilachery, Madurai 3193007 5.2 RE re 6/24p 6/24 ns II BE: Mod-Severe NPDR/CSME 296 400 140 120 41 RE 6/9 6/9 170 320
18 Green Kunhaysha 70 F Vadakara, Kozhikode 3204785 6.4 LE le 6/12 6/12 lc BE: Severe NPDR/CSME 207 223 150 100 49 LE 6/9 6/9 180 112
19 yellow Indira 56 F Kandalloor, Allepey 3208489 8.9 RE re: 6/36 6/36 lc BE: Severe NPDR/CSME 630 100 100 60 RE 6/18 6/18 415
20 yellow Indira 56 F Kandalloor, Allepey 3208489 8.9 LE le: 6/6p 6/6 lc BE: Severe NPDR/CSME 188 328 100 100 34 LE 6/6 6/6 160 265
21 yellow Seshan 52 M Simmakkal, Madurai 2906835 8.1 RE re: 6/36p 6/36 early imc BE: Severe NPDR/CSME 603 120 100 102 RE 6/36 6/36 384
22 Green Kalaiselvi 48 F Annamalai Nagar, Tanjore 3143412 6.6 RE re 6/18 6/18 imc be: severe npdr/csme 319 100 100 29 RE 6/9 6/9 250
23 Green Kalaiselvi 48 F Annamalai Nagar, Tanjore 3143412 6.6 LE le 6/24 6/24 imc be: severe npdr/csme 375 120 100 42 LE 6/18p 6/18 363
24 Green Seshan 52 M Simmakkal, Madurai 2906835 8.1 LE le: 6/12p 6/12 early imc BE: Severe NPDR/CSME 415 130 100 94 LE 6/12 6/12 319
25 Yellow Abdul Wahab 65 M Mudukulathur, Ramanathapuram 3128738 6.2 LE le: 6/9 6/9 wnl Be: Mod NPDR/CSME 248 453 140 100 46 LE 6/9p 6/9 186 290
26 Yellow Anthony P.C. 74 M Ramakkal Medu P.O., Idukki, Kerela 3214535 5.5 RE re: 6/12p 6/12 early imc Be:Severe NPDR/CSME 363 150 100 61 RE 6/12 6/12 250
27 green Karishma Begum 55 F Sattankulam, Ramanathapuram 3184299 5.0 LE le 6/12 6/12 lc LE: Mod npdr csme 255 439 110 100 40 LE 6/9 6/9 210 294
28 green Kesari das 48 F Thiruvarambu, Kanyakumari 3017220 8.0 RE 6/6p 6/6 lc BE: Mod-Severe NPDR/CSME 241 391 140 100 36 le 6/6 6/6 160 265
29 green Ayyasamy 73 M Valangaiman, Thiruvarur 3204341 8.6 RE re: 6/18p 6/18 pciol BE: Severe NPDR/CSME 625 110 100 34 re 6/9p 6/9 600 100, 100, 41 390u
30 Yellow Paneer Selvam 58 M Virudhunagar 3235638 6.4 RE re 6/18 6/18 wnl BE: Severe NPDR/CSME 410 90 100 42 Re 6/9p 6/9 240
31 Yellow Durairaj 42 M Ramanathapuram 3128742 5.8 RE re 6/6p 6/6 wnl Re: Mod Npder with CSME 640 100 100 28 RE 6/6 6/6 218
32 Yellow Anthony P.C. 74 M Ramakkal Medu P.O., Idukki, Kerela 3214535 5.5 LE le: 6/18 6/18 early imc BE: Severe NPDR/CSME 420 150 100 52 LE 6/12 6/12 242
33 Yellow Chandra Devi 50 F Mettupatti, Vadipatti 2218268 6.9 RE re: 6/6p 6/6 wnl Be: Mod NPDR/CSME 170 327 130 100 84 RE 6/6 6/6 168 244
34 green Lakshmanan 40 M Thiruppalai, Madurai City 3235646 6.4 RE re: 6/6 6/6 wnl Be: Mod NPDR/CSME 199 383 100 100 53 RE 6/6 6/6 180 242
35 Yellow Chandra Devi 50 F Mettupatti, Vadipatti 2218268 6.9 LE le: 6/6p 6/6 wnl Be: Mod NPDR/CSME 327 431 130 100 72 RE 6/6 6/6 217 311
36 green Ayyanar 52 M Vellipattinam, Ramanathapuram 3240581 6.9 LE le: 6/9 6/9 lens changes LE: Mod npdr csme 184 440 120 100 78 le 6/6p 6/6 182 360
37 green Karuppaiah 57 M Sekkalai, Karaikudi 2571485 7.1 RE re:6/9 6/9 lc re: Mod - Severe NPDR/CSME 327 519 120 100 48 Re 6/6 6/6 240 410
38 yellow Karuppaiah 57 M Sekkalai, Karaikudi 2571485 7.1 RE le:6/9p 6/9 lc le: Mod - Severe NPDR/CSME 237 455 100 100 62 Re 6/6 6/6 186 270
39 Yellow Abdul Azeez 43 M Malapuram, Kerala 3235639 7.4 RE re: 6/6p 6/6 WNL BE: Severe NPDR/CSME 245 480 120 100 51 Re 6/6 6/6 211 326
40 Yellow Ponnammal 66 F Aruppukottai, Virudhunagar 3174419 5.6 RE re: 6/12p 6/12 pciol re: Mod - Severe NPDR/CSME 141 430 100 100 135 Re 6/9 6/9 136 260
41 Yellow Jose K.J 59 M Kottayam 3253919 7.2 RE re: 6/24 6/24 early pscc re: Disc pallor/ Severe NPDR/CSME 163 435 80 100 80 RE 6/18 6/18 156 230
42 Yellow Ramalingam 63 M Samiyarpatti, Athoor, Dindigul 3130521 5.8 RE re: 6/9p 6/9 WNL re: Mod - Severe NPDR/CSME 210 396 110 100 46 RE 6/9 6/9 186 260
43 green Jose K.J 59 M Kottayam 3253919 7.2 LE le: 6/6p 6/6 early pscc LE: severe npdr csme 151 472 100 100 64 le 6/6 6/6 148 302
44 green Narayanasamy 70 M Sayanethal, Virudachalam 3257358 6.5 LE le: 6/6p 6/6 pciol LE: Mod npdr csme 225 407 100 100 61 le 6/6 6/6 210 390
45 Yellow Sandavaliyan 57 M Vasantha Nagar, Madurai 3258577 7.4 RE re: 6/6 6/6 lc re: severe npdr csme 156 326 100 80 39 re 6/6 6/6 151 216
46 green Sandavaliyan 57 M Vasantha Nagar, Madurai 3258577 7.4 LE le: 6/6p 6/6 lc LE: severe npdr csme 170 348 100 80 47 le 6/6 6/6 165 254
47 yellow Sivakumar 60 M Aruppukottai, Virudhunagar 2987762 6.9 LE le: 6/12p 6/12 pciol LE: Mod npdr csme 320 120 100 46 le 6/9 6/9 236
48 Yellow Rajamani 60 F K.K.Nagar, Madurai 2542384 8.4 LE le: 6/24 6/24 pciol LE: Mod npdr csme 215 326 80 100 24 le 6/12p 6/12 170 214
MATER CHART 
49 Yellow Rengaiah 58 M Devapatti, Pudukottai fh-1167618 5.4 LE le: 6/12p 6/12 lc LE: severe npdr csme 163 387 110 100 28 le 6/9 6/6 148 217
50 green Karuppaiah 57 M Sekkalai, Karaikudi 2571485 8.3 LE le: 6/9p 6/6 early imc LE: Mod npdr csme 412 487 80 100 51 le 6/9 6/9 254 311
51 Yellow Vellaisamy 60 M Kumaran Thirunagar, Dindigul 3169450 5.6 LE le: 6/6p 6/6 wnl LE: Mod npdr csme 227 455 90 100 32 le 6/6p 6/6 203 264
52 green Ravichandran 53 M Philomina Nagar, Tanjore 2910825 6.2 LE le: 6/6p 6/6 pciol LE: severe npdr csme 187 380 150 80 22 le 6/6 6/6 166 224
53 green Chandra 58 F Visaloor, Tanjore 3321651 7.4 RE RE: 6/9 6/6 lens changes re: severe npdr csme 160 295 160 100 34 le 6/9 6/9 164 270
54 green Ayyammal 51 F Pillayar Koil street, sholavandan, vadiapptty3325541 5.6 RE re:6/6 6/6 lc re: Mod  NPDR/CSME 286 380 120 100 70 RE 6/6 6/6 210 286
55 green Ayyammal 51 F Pillayar Koil street, sholavandan, vadiapptty3325541 5.6 LE le: 6/6 6/6 lc LE: Mod npdr csme 490 110 100 60 le 6/9 6/9 360
56 Yellow Palanisamy 56 M Dharapuram 2923207 6.0 RE re: 6/6 6/6 wnl RE: mod npdr csme 185 356 100 100 34 re 6/6 6/6 160 267
57 green Palanisamy 56 M Dharapuram 2923207 6.0 LE le: 6/6 6/6 wnl LE: severe npdr csme 165 360 110 100 42 le 6/6 6/6 155 282
58 green Sivaranjini 57 M Vellipatinam, Ramnad 3251256 8.5 LE le: 6/12p 6/12 lens changes LE: Mod npdr csme 184 426 120 100 75 le 6/9 6/9 178 284
59 green Muthuvel 60 M Boopalathi Street, Rajapalayam 3237426 6.4 Re re: 6/9 6/9 lens changes re: Mod - Severe NPDR/CSME 144 378 120 80 60 RE 6/9 6/9 140 280
60 green Thilakavatthi 57 F Pudur, Madurai 3248231 7.9 RE re" 6/12p 6/12 WNL re: severe npdr csme 311 446 110 100 64 RE: 6/9 6/9 236 312
61 Yellow Pandiaraj 43 M Thirunagar, Dindigul 3269455 6.1 Re Re 6/6p 6/6 WNL RE: mod npdr csme 241 466 90 100 66 RE: 6/6 6/6 214 316
62 Yellow Narayanan 68 M KK Nagar, Madurai 3256481 7.2 RE Re: 6/12p 6/12 pciol re: severe npdr csme 211 383 100 100 56 Re: 6/9 6/9 182 226
63 green Thasleema Begum 66 F Kollam, Kerela 3168426 8.2 RE Re: 6/18 6/18 pciol re: severe npdr csme 362 480 100 100 42 Re: 6/9 6/9 264 344
64 Yellow Thasleema Begum 66 F Kollam, Kerela 3168426 8.2 LE Re: 6/18p 6/18 pciol LE: severe npdr csme 341 466 90 100 38 Le: 6/12 6/12 216 260
65 Yellow Jeyakumar 46 M Chockikulam, Madurai 3361412 5.8 RE Re: 6/9p 6/6 WNL RE: mod npdr csme 260 364 110 100 58 Re: 6/6 6/6 204 268
66 green Jeyakumar 46 M Chockikulam, Madurai 3361412 5.8 LE le: 6/9 6/9 WNL LE: Mod npdr csme 221 312 120 100 64 Le: 6/6p 6/6 208 256
67 green K.S.Raju 58 M Thillai Nagar, Trichy 3352489 7.1 LE LE 6/24 6/24 lens changes LE: Mod - Severe NPDR/CSME 382 471 110 100 38 LE: 6/18p 6/18 368 454 120, 100, 42  320u
68 green Joseph K.J 68 M Kottayam 3331624 7.5 RE Re: 6/12p 6/12 pciol re: severe npdr csme 318 512 110 100 54 Re: 6/9 6/6 246 390
69 green Joseph K.J 68 M Kottayam 3331624 7.4 LE LE: 6/18p 6/18 pciol LE: severe npdr csme 346 490 120 100 62 LE: 6/12 6/12 260 344
70 Yellow Manickam 42 M Vellakoil 3334296 6.9 RE RE 6/18 6/18 WNL re: severe npdr csme 324 542 100 100 48 re: 6/9 6/9 218 304
71 Yellow Manickam 42 M Vellakoil 3334296 6.9 LE le: 6/12p 6/12 WNL LE: severe npdr csme 352 512 90 100 52 le: 6/6p 6/6 232 268
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1 Yellow Velayudhan 58 M Ezhachery, Kottayam 3087774 6.5 RE R-6/9 6/9 early imc R:Mod NPDR/CSME 496 100 100 25 RE 6/9 6/9 284
2 Green Savithri 55 F Mattaparai, Dindigul 3098148 5.8 RE R-6/18 6/18 early IMC RE: Mod NPDR/CSME 243 507 90 100 55 RE 6/9 6/9 210 380
3 Green Savithri 55 F Mattaparai, Dindigul 3098148 5.8 LE LE - 6/9p 6/9 Early IMC LE: Mod NPDR/CSME 235 455 90 100 32 LE 6/9 6/9 216 340
4 Yellow Dhanapackiam 52 F Kambilampatti, Dindigul 3098234 6.8 RE R-6/12P 6/12 lens changes RE: Mod-Severe NPDR/CSME Hard Exudate plaque-parafoveal290 110 100 111 RE 6/9 6/9 171
5 Green Dhanapackiam 52 F Kambilampatti, Dindigul 3098234 6.8 LE L-6/6P 6/6 lens changes LE: Mod NPDR/CSME 452 100 100 81 LE 6/6p 6/6 239
6 Green Shahul Hameed 62 M Athirampatinam, Tanjore 3065765 7.2 RE R - 6/18 6/18 IMC (PSCC) RE- severe NPDR/CSME 370 100 100 39 RE 6/12 6/12 254
7 Green Manickam 70 M Athoor, Dindigul 3078366 4.9 LE le - 6/6p 6/6 wnl L: ModNPDR/CSME 484 110 100 25 LE 6/6 6/6 420
8 Yellow Ramamoorthy MS 42 M Aruuppukottai, Virudunagar 3100503 5.5 RE RE 6/24 6/24 wnl RE: severe npdr/csme 469 90 100 62 re 6/9 6/9 310
9 Green Ramamoorthy MS 42 M Aruuppukottai, Virudunagar 3100503 5.5 LE LE 6/24p 6/24 WNL LE: severe npdr/csme 647 70 100 21 re 6/12 6/12 416
10 Yellow Salahudeen 60 M Kollam, Kerela 3109224 6.4 RE R 6/12p 6/12 wnl Re: Mod NPDR CSME 423 120 100 38 RE 6/6p 6/6 226
11 Green Dharmarajan 65 M Santhaipettai, Madurai 3168421 6.9 RE Re: 6/24 6/24 lens changes Re: Severe NPDR CSME with CME PVD 660 120 100 42 RE 6/18 6/18 480
12 Yellow Maragatham 40 F Nethaji Road, Madurai 3106807 7.2 RE Re 6/9p 6/9 Wnl BE: Mod NPDR/CSME 188 399 160 100 11 RE 6/9 6/9 186 348
13 Yellow Suganthan 61 M Varkala, Trivandrum 3133977 8.3 LE LE 6/12 6/12 LC LE: SEVERE NPDR/CSME 334 90 100 25 RE 6/9p 6/9 214
14 Yellow Subramnaniam 63 M jayanthi Nagar, Madurai 3156654 7.9 RE re 6/12p 6/12 wnl BE: Mod NPDR/CSME 311 511 150 150 47 RE 6/9 6/9 220 344
15 Yellow Aysha Beevi 56 F Thasiladar Nagar, Madurai 3167633 8.4 LE LE 6/18 6/18 wnl BE: Mod-Severe NPDR/CSME 309 482 120 100 24 LE 6/12 6/12 190 312
16 Yellow Premchand 50 M Trivandrum 3190307 8.6 RE re 6/9 6/9 wnl BE: Mod-Severe NPDR/CSME 346 120 100 42 RE 6/9 6/9 391 110, 100, 51 270u
17 Yellow Rabiyammul 72 F Vilachery, Madurai 3193007 5.2 RE re 6/24p 6/24 ns II BE: Mod-Severe NPDR/CSME 296 400 140 120 41 RE 6/9 6/9 170 320
18 Green Kunhaysha 70 F Vadakara, Kozhikode 3204785 6.4 LE le 6/12 6/12 lc BE: Severe NPDR/CSME 207 223 150 100 49 LE 6/9 6/9 180 112
19 yellow Indira 56 F Kandalloor, Allepey 3208489 8.9 RE re: 6/36 6/36 lc BE: Severe NPDR/CSME 630 100 100 60 RE 6/18 6/18 415
20 yellow Indira 56 F Kandalloor, Allepey 3208489 8.9 LE le: 6/6p 6/6 lc BE: Severe NPDR/CSME 188 328 100 100 34 LE 6/6 6/6 160 265
21 yellow Seshan 52 M Simmakkal, Madurai 2906835 8.1 RE re: 6/36p 6/36 early imc BE: Severe NPDR/CSME 603 120 100 102 RE 6/36 6/36 384
22 Green Kalaiselvi 48 F Annamalai Nagar, Tanjore 3143412 6.6 RE re 6/18 6/18 imc be: severe npdr/csme 319 100 100 29 RE 6/9 6/9 250
23 Green Kalaiselvi 48 F Annamalai Nagar, Tanjore 3143412 6.6 LE le 6/24 6/24 imc be: severe npdr/csme 375 120 100 42 LE 6/18p 6/18 363
24 Green Seshan 52 M Simmakkal, Madurai 2906835 8.1 LE le: 6/12p 6/12 early imc BE: Severe NPDR/CSME 415 130 100 94 LE 6/12 6/12 319
25 Yellow Abdul Wahab 65 M Mudukulathur, Ramanathapuram 3128738 6.2 LE le: 6/9 6/9 wnl Be: Mod NPDR/CSME 248 453 140 100 46 LE 6/9p 6/9 186 290
26 Yellow Anthony P.C. 74 M Ramakkal Medu P.O., Idukki, Kerela 3214535 5.5 RE re: 6/12p 6/12 early imc Be:Severe NPDR/CSME 363 150 100 61 RE 6/12 6/12 250
27 green Karishma Begum 55 F Sattankulam, Ramanathapuram 3184299 5.0 LE le 6/12 6/12 lc LE: Mod npdr csme 255 439 110 100 40 LE 6/9 6/9 210 294
28 green Kesari das 48 F Thiruvarambu, Kanyakumari 3017220 8.0 RE 6/6p 6/6 lc BE: Mod-Severe NPDR/CSME 241 391 140 100 36 le 6/6 6/6 160 265
29 green Ayyasamy 73 M Valangaiman, Thiruvarur 3204341 8.6 RE re: 6/18p 6/18 pciol BE: Severe NPDR/CSME 625 110 100 34 re 6/9p 6/9 600 100, 100, 41 390u
30 Yellow Paneer Selvam 58 M Virudhunagar 3235638 6.4 RE re 6/18 6/18 wnl BE: Severe NPDR/CSME 410 90 100 42 Re 6/9p 6/9 240
31 Yellow Durairaj 42 M Ramanathapuram 3128742 5.8 RE re 6/6p 6/6 wnl Re: Mod Npder with CSME 640 100 100 28 RE 6/6 6/6 218
32 Yellow Anthony P.C. 74 M Ramakkal Medu P.O., Idukki, Kerela 3214535 5.5 LE le: 6/18 6/18 early imc BE: Severe NPDR/CSME 420 150 100 52 LE 6/12 6/12 242
33 Yellow Chandra Devi 50 F Mettupatti, Vadipatti 2218268 6.9 RE re: 6/6p 6/6 wnl Be: Mod NPDR/CSME 170 327 130 100 84 RE 6/6 6/6 168 244
34 green Lakshmanan 40 M Thiruppalai, Madurai City 3235646 6.4 RE re: 6/6 6/6 wnl Be: Mod NPDR/CSME 199 383 100 100 53 RE 6/6 6/6 180 242
35 Yellow Chandra Devi 50 F Mettupatti, Vadipatti 2218268 6.9 LE le: 6/6p 6/6 wnl Be: Mod NPDR/CSME 327 431 130 100 72 RE 6/6 6/6 217 311
36 green Ayyanar 52 M Vellipattinam, Ramanathapuram 3240581 6.9 LE le: 6/9 6/9 lens changes LE: Mod npdr csme 184 440 120 100 78 le 6/6p 6/6 182 360
37 green Karuppaiah 57 M Sekkalai, Karaikudi 2571485 7.1 RE re:6/9 6/9 lc re: Mod - Severe NPDR/CSME 327 519 120 100 48 Re 6/6 6/6 240 410
38 yellow Karuppaiah 57 M Sekkalai, Karaikudi 2571485 7.1 RE le:6/9p 6/9 lc le: Mod - Severe NPDR/CSME 237 455 100 100 62 Re 6/6 6/6 186 270
39 Yellow Abdul Azeez 43 M Malapuram, Kerala 3235639 7.4 RE re: 6/6p 6/6 WNL BE: Severe NPDR/CSME 245 480 120 100 51 Re 6/6 6/6 211 326
40 Yellow Ponnammal 66 F Aruppukottai, Virudhunagar 3174419 5.6 RE re: 6/12p 6/12 pciol re: Mod - Severe NPDR/CSME 141 430 100 100 135 Re 6/9 6/9 136 260
41 Yellow Jose K.J 59 M Kottayam 3253919 7.2 RE re: 6/24 6/24 early pscc re: Disc pallor/ Severe NPDR/CSME 163 435 80 100 80 RE 6/18 6/18 156 230
42 Yellow Ramalingam 63 M Samiyarpatti, Athoor, Dindigul 3130521 5.8 RE re: 6/9p 6/9 WNL re: Mod - Severe NPDR/CSME 210 396 110 100 46 RE 6/9 6/9 186 260
43 green Jose K.J 59 M Kottayam 3253919 7.2 LE le: 6/6p 6/6 early pscc LE: severe npdr csme 151 472 100 100 64 le 6/6 6/6 148 302
44 green Narayanasamy 70 M Sayanethal, Virudachalam 3257358 6.5 LE le: 6/6p 6/6 pciol LE: Mod npdr csme 225 407 100 100 61 le 6/6 6/6 210 390
45 Yellow Sandavaliyan 57 M Vasantha Nagar, Madurai 3258577 7.4 RE re: 6/6 6/6 lc re: severe npdr csme 156 326 100 80 39 re 6/6 6/6 151 216
46 green Sandavaliyan 57 M Vasantha Nagar, Madurai 3258577 7.4 LE le: 6/6p 6/6 lc LE: severe npdr csme 170 348 100 80 47 le 6/6 6/6 165 254
47 yellow Sivakumar 60 M Aruppukottai, Virudhunagar 2987762 6.9 LE le: 6/12p 6/12 pciol LE: Mod npdr csme 320 120 100 46 le 6/9 6/9 236
48 Yellow Rajamani 60 F K.K.Nagar, Madurai 2542384 8.4 LE le: 6/24 6/24 pciol LE: Mod npdr csme 215 326 80 100 24 le 6/12p 6/12 170 214
MATER CHART 
49 Yellow Rengaiah 58 M Devapatti, Pudukottai fh-1167618 5.4 LE le: 6/12p 6/12 lc LE: severe npdr csme 163 387 110 100 28 le 6/9 6/6 148 217
50 green Karuppaiah 57 M Sekkalai, Karaikudi 2571485 8.3 LE le: 6/9p 6/6 early imc LE: Mod npdr csme 412 487 80 100 51 le 6/9 6/9 254 311
51 Yellow Vellaisamy 60 M Kumaran Thirunagar, Dindigul 3169450 5.6 LE le: 6/6p 6/6 wnl LE: Mod npdr csme 227 455 90 100 32 le 6/6p 6/6 203 264
52 green Ravichandran 53 M Philomina Nagar, Tanjore 2910825 6.2 LE le: 6/6p 6/6 pciol LE: severe npdr csme 187 380 150 80 22 le 6/6 6/6 166 224
53 green Chandra 58 F Visaloor, Tanjore 3321651 7.4 RE RE: 6/9 6/6 lens changes re: severe npdr csme 160 295 160 100 34 le 6/9 6/9 164 270
54 green Ayyammal 51 F Pillayar Koil street, sholavandan, vadiapptty3325541 5.6 RE re:6/6 6/6 lc re: Mod  NPDR/CSME 286 380 120 100 70 RE 6/6 6/6 210 286
55 green Ayyammal 51 F Pillayar Koil street, sholavandan, vadiapptty3325541 5.6 LE le: 6/6 6/6 lc LE: Mod npdr csme 490 110 100 60 le 6/9 6/9 360
56 Yellow Palanisamy 56 M Dharapuram 2923207 6.0 RE re: 6/6 6/6 wnl RE: mod npdr csme 185 356 100 100 34 re 6/6 6/6 160 267
57 green Palanisamy 56 M Dharapuram 2923207 6.0 LE le: 6/6 6/6 wnl LE: severe npdr csme 165 360 110 100 42 le 6/6 6/6 155 282
58 green Sivaranjini 57 M Vellipatinam, Ramnad 3251256 8.5 LE le: 6/12p 6/12 lens changes LE: Mod npdr csme 184 426 120 100 75 le 6/9 6/9 178 284
59 green Muthuvel 60 M Boopalathi Street, Rajapalayam 3237426 6.4 Re re: 6/9 6/9 lens changes re: Mod - Severe NPDR/CSME 144 378 120 80 60 RE 6/9 6/9 140 280
60 green Thilakavatthi 57 F Pudur, Madurai 3248231 7.9 RE re" 6/12p 6/12 WNL re: severe npdr csme 311 446 110 100 64 RE: 6/9 6/9 236 312
61 Yellow Pandiaraj 43 M Thirunagar, Dindigul 3269455 6.1 Re Re 6/6p 6/6 WNL RE: mod npdr csme 241 466 90 100 66 RE: 6/6 6/6 214 316
62 Yellow Narayanan 68 M KK Nagar, Madurai 3256481 7.2 RE Re: 6/12p 6/12 pciol re: severe npdr csme 211 383 100 100 56 Re: 6/9 6/9 182 226
63 green Thasleema Begum 66 F Kollam, Kerela 3168426 8.2 RE Re: 6/18 6/18 pciol re: severe npdr csme 362 480 100 100 42 Re: 6/9 6/9 264 344
64 Yellow Thasleema Begum 66 F Kollam, Kerela 3168426 8.2 LE Re: 6/18p 6/18 pciol LE: severe npdr csme 341 466 90 100 38 Le: 6/12 6/12 216 260
65 Yellow Jeyakumar 46 M Chockikulam, Madurai 3361412 5.8 RE Re: 6/9p 6/6 WNL RE: mod npdr csme 260 364 110 100 58 Re: 6/6 6/6 204 268
66 green Jeyakumar 46 M Chockikulam, Madurai 3361412 5.8 LE le: 6/9 6/9 WNL LE: Mod npdr csme 221 312 120 100 64 Le: 6/6p 6/6 208 256
67 green K.S.Raju 58 M Thillai Nagar, Trichy 3352489 7.1 LE LE 6/24 6/24 lens changes LE: Mod - Severe NPDR/CSME 382 471 110 100 38 LE: 6/18p 6/18 368 454 120, 100, 42  320u
68 green Joseph K.J 68 M Kottayam 3331624 7.5 RE Re: 6/12p 6/12 pciol re: severe npdr csme 318 512 110 100 54 Re: 6/9 6/6 246 390
69 green Joseph K.J 68 M Kottayam 3331624 7.4 LE LE: 6/18p 6/18 pciol LE: severe npdr csme 346 490 120 100 62 LE: 6/12 6/12 260 344
70 Yellow Manickam 42 M Vellakoil 3334296 6.9 RE RE 6/18 6/18 WNL re: severe npdr csme 324 542 100 100 48 re: 6/9 6/9 218 304
71 Yellow Manickam 42 M Vellakoil 3334296 6.9 LE le: 6/12p 6/12 WNL LE: severe npdr csme 352 512 90 100 52 le: 6/6p 6/6 232 268
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1 Yellow Velayudhan 58 M Ezhachery, Kottayam 3087774 6.5 RE R-6/9 6/9 early imc R:Mod NPDR/CSME 496 100 100 25 RE 6/9 6/9 284
2 Green Savithri 55 F Mattaparai, Dindigul 3098148 5.8 RE R-6/18 6/18 early IMC RE: Mod NPDR/CSME 243 507 90 100 55 RE 6/9 6/9 210 380
3 Green Savithri 55 F Mattaparai, Dindigul 3098148 5.8 LE LE - 6/9p 6/9 Early IMC LE: Mod NPDR/CSME 235 455 90 100 32 LE 6/9 6/9 216 340
4 Yellow Dhanapackiam 52 F Kambilampatti, Dindigul 3098234 6.8 RE R-6/12P 6/12 lens changes RE: Mod-Severe NPDR/CSME Hard Exudate plaque-parafoveal290 110 100 111 RE 6/9 6/9 171
5 Green Dhanapackiam 52 F Kambilampatti, Dindigul 3098234 6.8 LE L-6/6P 6/6 lens changes LE: Mod NPDR/CSME 452 100 100 81 LE 6/6p 6/6 239
6 Green Shahul Hameed 62 M Athirampatinam, Tanjore 3065765 7.2 RE R - 6/18 6/18 IMC (PSCC) RE- severe NPDR/CSME 370 100 100 39 RE 6/12 6/12 254
7 Green Manickam 70 M Athoor, Dindigul 3078366 4.9 LE le - 6/6p 6/6 wnl L: ModNPDR/CSME 484 110 100 25 LE 6/6 6/6 420
8 Yellow Ramamoorthy MS 42 M Aruuppukottai, Virudunagar 3100503 5.5 RE RE 6/24 6/24 wnl RE: severe npdr/csme 469 90 100 62 re 6/9 6/9 310
9 Green Ramamoorthy MS 42 M Aruuppukottai, Virudunagar 3100503 5.5 LE LE 6/24p 6/24 WNL LE: severe npdr/csme 647 70 100 21 re 6/12 6/12 416
10 Yellow Salahudeen 60 M Kollam, Kerela 3109224 6.4 RE R 6/12p 6/12 wnl Re: Mod NPDR CSME 423 120 100 38 RE 6/6p 6/6 226
11 Green Dharmarajan 65 M Santhaipettai, Madurai 3168421 6.9 RE Re: 6/24 6/24 lens changes Re: Severe NPDR CSME with CME PVD 660 120 100 42 RE 6/18 6/18 480
12 Yellow Maragatham 40 F Nethaji Road, Madurai 3106807 7.2 RE Re 6/9p 6/9 Wnl BE: Mod NPDR/CSME 188 399 160 100 11 RE 6/9 6/9 186 348
13 Yellow Suganthan 61 M Varkala, Trivandrum 3133977 8.3 LE LE 6/12 6/12 LC LE: SEVERE NPDR/CSME 334 90 100 25 RE 6/9p 6/9 214
14 Yellow Subramnaniam 63 M jayanthi Nagar, Madurai 3156654 7.9 RE re 6/12p 6/12 wnl BE: Mod NPDR/CSME 311 511 150 150 47 RE 6/9 6/9 220 344
15 Yellow Aysha Beevi 56 F Thasiladar Nagar, Madurai 3167633 8.4 LE LE 6/18 6/18 wnl BE: Mod-Severe NPDR/CSME 309 482 120 100 24 LE 6/12 6/12 190 312
16 Yellow Premchand 50 M Trivandrum 3190307 8.6 RE re 6/9 6/9 wnl BE: Mod-Severe NPDR/CSME 346 120 100 42 RE 6/9 6/9 391 110, 100, 51 270u
17 Yellow Rabiyammul 72 F Vilachery, Madurai 3193007 5.2 RE re 6/24p 6/24 ns II BE: Mod-Severe NPDR/CSME 296 400 140 120 41 RE 6/9 6/9 170 320
18 Green Kunhaysha 70 F Vadakara, Kozhikode 3204785 6.4 LE le 6/12 6/12 lc BE: Severe NPDR/CSME 207 223 150 100 49 LE 6/9 6/9 180 112
19 yellow Indira 56 F Kandalloor, Allepey 3208489 8.9 RE re: 6/36 6/36 lc BE: Severe NPDR/CSME 630 100 100 60 RE 6/18 6/18 415
20 yellow Indira 56 F Kandalloor, Allepey 3208489 8.9 LE le: 6/6p 6/6 lc BE: Severe NPDR/CSME 188 328 100 100 34 LE 6/6 6/6 160 265
21 yellow Seshan 52 M Simmakkal, Madurai 2906835 8.1 RE re: 6/36p 6/36 early imc BE: Severe NPDR/CSME 603 120 100 102 RE 6/36 6/36 384
22 Green Kalaiselvi 48 F Annamalai Nagar, Tanjore 3143412 6.6 RE re 6/18 6/18 imc be: severe npdr/csme 319 100 100 29 RE 6/9 6/9 250
23 Green Kalaiselvi 48 F Annamalai Nagar, Tanjore 3143412 6.6 LE le 6/24 6/24 imc be: severe npdr/csme 375 120 100 42 LE 6/18p 6/18 363
24 Green Seshan 52 M Simmakkal, Madurai 2906835 8.1 LE le: 6/12p 6/12 early imc BE: Severe NPDR/CSME 415 130 100 94 LE 6/12 6/12 319
25 Yellow Abdul Wahab 65 M Mudukulathur, Ramanathapuram 3128738 6.2 LE le: 6/9 6/9 wnl Be: Mod NPDR/CSME 248 453 140 100 46 LE 6/9p 6/9 186 290
26 Yellow Anthony P.C. 74 M Ramakkal Medu P.O., Idukki, Kerela 3214535 5.5 RE re: 6/12p 6/12 early imc Be:Severe NPDR/CSME 363 150 100 61 RE 6/12 6/12 250
27 green Karishma Begum 55 F Sattankulam, Ramanathapuram 3184299 5.0 LE le 6/12 6/12 lc LE: Mod npdr csme 255 439 110 100 40 LE 6/9 6/9 210 294
28 green Kesari das 48 F Thiruvarambu, Kanyakumari 3017220 8.0 RE 6/6p 6/6 lc BE: Mod-Severe NPDR/CSME 241 391 140 100 36 le 6/6 6/6 160 265
29 green Ayyasamy 73 M Valangaiman, Thiruvarur 3204341 8.6 RE re: 6/18p 6/18 pciol BE: Severe NPDR/CSME 625 110 100 34 re 6/9p 6/9 600 100, 100, 41 390u
30 Yellow Paneer Selvam 58 M Virudhunagar 3235638 6.4 RE re 6/18 6/18 wnl BE: Severe NPDR/CSME 410 90 100 42 Re 6/9p 6/9 240
31 Yellow Durairaj 42 M Ramanathapuram 3128742 5.8 RE re 6/6p 6/6 wnl Re: Mod Npder with CSME 640 100 100 28 RE 6/6 6/6 218
32 Yellow Anthony P.C. 74 M Ramakkal Medu P.O., Idukki, Kerela 3214535 5.5 LE le: 6/18 6/18 early imc BE: Severe NPDR/CSME 420 150 100 52 LE 6/12 6/12 242
33 Yellow Chandra Devi 50 F Mettupatti, Vadipatti 2218268 6.9 RE re: 6/6p 6/6 wnl Be: Mod NPDR/CSME 170 327 130 100 84 RE 6/6 6/6 168 244
34 green Lakshmanan 40 M Thiruppalai, Madurai City 3235646 6.4 RE re: 6/6 6/6 wnl Be: Mod NPDR/CSME 199 383 100 100 53 RE 6/6 6/6 180 242
35 Yellow Chandra Devi 50 F Mettupatti, Vadipatti 2218268 6.9 LE le: 6/6p 6/6 wnl Be: Mod NPDR/CSME 327 431 130 100 72 RE 6/6 6/6 217 311
36 green Ayyanar 52 M Vellipattinam, Ramanathapuram 3240581 6.9 LE le: 6/9 6/9 lens changes LE: Mod npdr csme 184 440 120 100 78 le 6/6p 6/6 182 360
37 green Karuppaiah 57 M Sekkalai, Karaikudi 2571485 7.1 RE re:6/9 6/9 lc re: Mod - Severe NPDR/CSME 327 519 120 100 48 Re 6/6 6/6 240 410
38 yellow Karuppaiah 57 M Sekkalai, Karaikudi 2571485 7.1 RE le:6/9p 6/9 lc le: Mod - Severe NPDR/CSME 237 455 100 100 62 Re 6/6 6/6 186 270
39 Yellow Abdul Azeez 43 M Malapuram, Kerala 3235639 7.4 RE re: 6/6p 6/6 WNL BE: Severe NPDR/CSME 245 480 120 100 51 Re 6/6 6/6 211 326
40 Yellow Ponnammal 66 F Aruppukottai, Virudhunagar 3174419 5.6 RE re: 6/12p 6/12 pciol re: Mod - Severe NPDR/CSME 141 430 100 100 135 Re 6/9 6/9 136 260
41 Yellow Jose K.J 59 M Kottayam 3253919 7.2 RE re: 6/24 6/24 early pscc re: Disc pallor/ Severe NPDR/CSME 163 435 80 100 80 RE 6/18 6/18 156 230
42 Yellow Ramalingam 63 M Samiyarpatti, Athoor, Dindigul 3130521 5.8 RE re: 6/9p 6/9 WNL re: Mod - Severe NPDR/CSME 210 396 110 100 46 RE 6/9 6/9 186 260
43 green Jose K.J 59 M Kottayam 3253919 7.2 LE le: 6/6p 6/6 early pscc LE: severe npdr csme 151 472 100 100 64 le 6/6 6/6 148 302
44 green Narayanasamy 70 M Sayanethal, Virudachalam 3257358 6.5 LE le: 6/6p 6/6 pciol LE: Mod npdr csme 225 407 100 100 61 le 6/6 6/6 210 390
45 Yellow Sandavaliyan 57 M Vasantha Nagar, Madurai 3258577 7.4 RE re: 6/6 6/6 lc re: severe npdr csme 156 326 100 80 39 re 6/6 6/6 151 216
46 green Sandavaliyan 57 M Vasantha Nagar, Madurai 3258577 7.4 LE le: 6/6p 6/6 lc LE: severe npdr csme 170 348 100 80 47 le 6/6 6/6 165 254
47 yellow Sivakumar 60 M Aruppukottai, Virudhunagar 2987762 6.9 LE le: 6/12p 6/12 pciol LE: Mod npdr csme 320 120 100 46 le 6/9 6/9 236
48 Yellow Rajamani 60 F K.K.Nagar, Madurai 2542384 8.4 LE le: 6/24 6/24 pciol LE: Mod npdr csme 215 326 80 100 24 le 6/12p 6/12 170 214
MATER CHART 
49 Yellow Rengaiah 58 M Devapatti, Pudukottai fh-1167618 5.4 LE le: 6/12p 6/12 lc LE: severe npdr csme 163 387 110 100 28 le 6/9 6/6 148 217
50 green Karuppaiah 57 M Sekkalai, Karaikudi 2571485 8.3 LE le: 6/9p 6/6 early imc LE: Mod npdr csme 412 487 80 100 51 le 6/9 6/9 254 311
51 Yellow Vellaisamy 60 M Kumaran Thirunagar, Dindigul 3169450 5.6 LE le: 6/6p 6/6 wnl LE: Mod npdr csme 227 455 90 100 32 le 6/6p 6/6 203 264
52 green Ravichandran 53 M Philomina Nagar, Tanjore 2910825 6.2 LE le: 6/6p 6/6 pciol LE: severe npdr csme 187 380 150 80 22 le 6/6 6/6 166 224
53 green Chandra 58 F Visaloor, Tanjore 3321651 7.4 RE RE: 6/9 6/6 lens changes re: severe npdr csme 160 295 160 100 34 le 6/9 6/9 164 270
54 green Ayyammal 51 F Pillayar Koil street, sholavandan, vadiapptty3325541 5.6 RE re:6/6 6/6 lc re: Mod  NPDR/CSME 286 380 120 100 70 RE 6/6 6/6 210 286
55 green Ayyammal 51 F Pillayar Koil street, sholavandan, vadiapptty3325541 5.6 LE le: 6/6 6/6 lc LE: Mod npdr csme 490 110 100 60 le 6/9 6/9 360
56 Yellow Palanisamy 56 M Dharapuram 2923207 6.0 RE re: 6/6 6/6 wnl RE: mod npdr csme 185 356 100 100 34 re 6/6 6/6 160 267
57 green Palanisamy 56 M Dharapuram 2923207 6.0 LE le: 6/6 6/6 wnl LE: severe npdr csme 165 360 110 100 42 le 6/6 6/6 155 282
58 green Sivaranjini 57 M Vellipatinam, Ramnad 3251256 8.5 LE le: 6/12p 6/12 lens changes LE: Mod npdr csme 184 426 120 100 75 le 6/9 6/9 178 284
59 green Muthuvel 60 M Boopalathi Street, Rajapalayam 3237426 6.4 Re re: 6/9 6/9 lens changes re: Mod - Severe NPDR/CSME 144 378 120 80 60 RE 6/9 6/9 140 280
60 green Thilakavatthi 57 F Pudur, Madurai 3248231 7.9 RE re" 6/12p 6/12 WNL re: severe npdr csme 311 446 110 100 64 RE: 6/9 6/9 236 312
61 Yellow Pandiaraj 43 M Thirunagar, Dindigul 3269455 6.1 Re Re 6/6p 6/6 WNL RE: mod npdr csme 241 466 90 100 66 RE: 6/6 6/6 214 316
62 Yellow Narayanan 68 M KK Nagar, Madurai 3256481 7.2 RE Re: 6/12p 6/12 pciol re: severe npdr csme 211 383 100 100 56 Re: 6/9 6/9 182 226
63 green Thasleema Begum 66 F Kollam, Kerela 3168426 8.2 RE Re: 6/18 6/18 pciol re: severe npdr csme 362 480 100 100 42 Re: 6/9 6/9 264 344
64 Yellow Thasleema Begum 66 F Kollam, Kerela 3168426 8.2 LE Re: 6/18p 6/18 pciol LE: severe npdr csme 341 466 90 100 38 Le: 6/12 6/12 216 260
65 Yellow Jeyakumar 46 M Chockikulam, Madurai 3361412 5.8 RE Re: 6/9p 6/6 WNL RE: mod npdr csme 260 364 110 100 58 Re: 6/6 6/6 204 268
66 green Jeyakumar 46 M Chockikulam, Madurai 3361412 5.8 LE le: 6/9 6/9 WNL LE: Mod npdr csme 221 312 120 100 64 Le: 6/6p 6/6 208 256
67 green K.S.Raju 58 M Thillai Nagar, Trichy 3352489 7.1 LE LE 6/24 6/24 lens changes LE: Mod - Severe NPDR/CSME 382 471 110 100 38 LE: 6/18p 6/18 368 454 120, 100, 42  320u
68 green Joseph K.J 68 M Kottayam 3331624 7.5 RE Re: 6/12p 6/12 pciol re: severe npdr csme 318 512 110 100 54 Re: 6/9 6/6 246 390
69 green Joseph K.J 68 M Kottayam 3331624 7.4 LE LE: 6/18p 6/18 pciol LE: severe npdr csme 346 490 120 100 62 LE: 6/12 6/12 260 344
70 Yellow Manickam 42 M Vellakoil 3334296 6.9 RE RE 6/18 6/18 WNL re: severe npdr csme 324 542 100 100 48 re: 6/9 6/9 218 304
71 Yellow Manickam 42 M Vellakoil 3334296 6.9 LE le: 6/12p 6/12 WNL LE: severe npdr csme 352 512 90 100 52 le: 6/6p 6/6 232 268
